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Global protease activity profiling for pancreatic cancer diagnosis and treatment 
By Sam Lacey Ivry 
Abstract 
 Proteolytic enzymes are central regulators of many of the hallmarks of cancer 
development and progression. Understanding how proteolytic activity evolves over the course of 
tumor development has the potential to provide mechanistic insights into disease progression and 
enable personalized treatment regimens. In this work, we sought to characterize protease activity 
in pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions. In order to study 
proteolysis in a global and unbiased manner, we applied a technology developed in our lab, 
termed Multiplex Substrate Profiling by Mass Spectrometry (MSP-MS). This technology utilizes 
a physicochemical diverse peptide library and mass spectrometry to determine protease 
specificity from various biological samples.  
 We first used MSP-MS to determine that a PDAC cell line secretes the lysosomal, 
aspartyl protease, cathepsin E. Secreted cathepsin E primarily exists as a zymogen and displays 
minimal activity at neutral pH. However, we were able to use MSP-MS to identify two substrates 
that were cleaved by the cathepsin E zymogen at pH 6.5, suggesting that this enzyme could be 
playing a proteolytic role in cancer progression. We also used our MSP-MS assay to assess 
global proteolytic activity in fluid from pancreatic cysts. Mucinous pancreatic cysts are precursor 
lesions to PDAC and should be resected if high-grade dysplasia or invasive cancer is suspected 
(HGD/IC). Unfortunately, clinicians are often unable to determine the stage preoperatively or 
differentiate mucinous from nonmucinous cysts, which are fully benign lesions of the pancreas. 
Through MSP-MS coupled with proteomic analysis, we identified three acid-activated proteases 
with increased activity in mucinous pancreatic cysts: cathepsin E, gastricsin, and tripeptidyl 
	 viii	
peptidyl peptidase 1 (TPP1). We developed a simple, fluorescence-based assay for analysis of all 
three proteases and applied this to a cohort of 110 cyst fluid samples. Analysis of gastricsin 
activity was 95% accurate for differentiating mucinous from nonmucinous cysts, significantly 
outperforming the most commonly applied biomarker, CEA. Combined analysis of gastricsin 
with CEA and cathepsin E improved accuracy to 99%. TPP1 activity demonstrated 89% 
sensitivity and 40% specificity for distinguishing mucinous cysts with HGD/IC from those with 
only LGD. This performance compares favorably to commonly assessed clinical and 
radiographic features.  Taken together, our results demonstrate that protease activity is 
differentially regulated in PDAC and activity analysis can serve as an accurate diagnostic tool for 
helping clinicians identify cysts with the highest potential for malignant transformation. 
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Chapter 1. Global substrate specificity profiling of post-translational modifying enzymes 
 
1.1 Abstract  
Enzymes that modify the proteome, referred to as post-translational modifying (PTM) enzymes, 
are central regulators of cellular signaling. Determining the substrate specificity of PTM 
enzymes is a critical step in unraveling their biological functions both in normal physiological 
processes and in disease states. Advances in peptide chemistry over the last century have enabled 
the rapid generation of peptide libraries for querying substrate recognition by PTM enzymes. In 
this review, we highlight various peptide-based approaches for analysis of PTM enzyme 
substrate specificity. We focus on the application of these technologies to proteases but also 
discuss specific examples in which they have been used to uncover the substrate specificity of 
other types of PTM enzymes, such as kinases. In particular, we highlight our Multiplex Substrate 
Profiling by Mass Spectrometry (MSP-MS) assay, which uses a rationally designed, 
physicochemically diverse library of tetradecapeptides. We show how this method has been 
applied to PTM enzymes to uncover biological function, as well as guide substrate and inhibitor 
design. We also briefly discuss how this technique can be combined with other methods to gain a 
systems-level understanding of PTM enzyme regulation and function.  
1.2 Introduction 
The primary mechanism by which the diversity of the proteome is increased is through the post-
translational modification of proteins. PTM enzymes are responsible for over 200 kinds of 
modifications of protein substrates and can be divided into two distinct mechanistic categories: 
(1) enzymes that hydrolyze peptide bonds (proteases) and (2) enzymes that covalently modify 
amino acid side chains. PTM enzymes constitute over 5% of the human genome but most have 
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yet to be fully characterized.1 An important aspect of understanding the functions of these 
enzymes requires developing in vitro assays in which their specificity and activity can be 
monitored. Although a variety of assays exist for profiling PTM enzyme specificity, there is 
particular value in assays in which post-translational modifications of peptide substrates are 
quantitatively and directly measured. To facilitate this type of assay format, researchers have 
taken advantage of synthetic peptide chemistry to develop large and diverse peptide libraries.  
 Peptide synthesis was pioneered by the work of Emil Fischer and Ernest Fourneau who 
synthesized the dipeptide glycylglycine in 1901. This work laid the foundation for subsequent 
advances in peptide synthesis with the Nobel Prize in Chemistry being awarded to Bruce 
Merrifield in 1984 for the development of solid-phase peptide synthesis (SPPS).2 Merrifield’s 
strategy involved assembly of a peptide chain in a stepwise manner with one end of the nascent 
peptide anchored to a solid resin until completion of synthesis. Covalent attachment of the 
growing peptide chain to a solid support renders it insoluble, which facilitates easier transition 
between synthetic steps, such as washing away excess reactant and byproduct. SPPS has been 
further streamlined over the last several decades and Fmoc SPPS is currently the most widely 
used synthetic strategy.3 Generating synthetic peptides using this technology gained popularity 
when biologists recognized that synthetic peptides could be used for antibody selection and 
production.4 Fmoc SPPS is now easily accomplished using highly automated work-flows.5,6 
 In this review, we first discuss how SPPS has been applied to generate large, highly 
diverse peptide libraries for the analysis of protease substrate specificity. We provide an 
overview of the various methods and describe several applications of how these methods have 
been applied to develop selective protease substrates and inhibitors. We extend this to a 
discussion of how SPPS has enabled the development of peptide libraries for determining the 
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specificity of other types of PTM enzymes. Proteome-derived peptide libraries as well as phage 
and bacterial display have also been widely applied for analysis of protease substrate specificity; 
however, these technologies are not the focus of the current review and have been reviewed 
elsewhere.7–9 
 
1.3 Peptide-based technologies for analysis of protease specificity 
Proteases are one of the largest classes of PTM enzymes, with over 550 encoded in the human 
genome.10 These enzymes are essential for normal cellular functions and are implicated in a 
variety of diseases, such as cancer, neurodegeneration, and blood clotting disorders. Because of 
the size and importance of this enzyme class, substantial effort has been put into the development 
of peptide-based technologies for determining protease substrate specificity. Proteases generally 
recognize substrates in an extended linear conformation, making this class of enzymes 
particularly amenable to analysis with peptide-based profiling methods.11 
 Traditionally, identification of protease substrates relied on relatively small collections of 
synthetic peptides with sequences derived from proteins that were known to be proteolyzed. 
Peptides would be incubated with a target protease and their cleavage assessed, generally 
through high-performance liquid chromatography (HPLC) with mass spectrometry for cleavage 
site identification.12 Once initial substrates were identified, new substrates with variations at 
select positions would be synthesized to explore subsite specificity. The development of 
colorimetric and fluorescent peptide substrates simplified cleavage assessment,13–15 however, 
defining protease substrate specificity remained an iterative and tedious process. Over the last 
two decades, this process has been transformed by the development of large and highly diverse 
peptide libraries. Table 1 summarizes some of the peptide-based technologies for analysis of 
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protease specificity. The information determined through these approaches can be used for a 
number of important applications. For example, selective substrates can be designed that enable 
the real-time monitoring of proteolysis in vitro and in vivo. Peptide substrates also can be 
converted into protease inhibitors through coupling to an electrophilic warhead. Furthermore, 
since proteolytic enzymes recognize their substrates as linear motifs of extended beta strands, 
specificity information can be used to prioritize potential endogenous substrates. For example, a 
number of computational approaches have been developed to predict caspase and granzyme B 
substrates using specificity data determined through peptide-based profiling methodologies.16,17 
Synthetic substrate synthesis, inhibitor design, and endogenous substrate identification are all 
critical steps in improving our understanding of the biological role of a given protease in both 
cellular function and pathogenesis.  
 
On-bead fluorescent peptide libraries 
In the late 1980s, Kahne et. al. developed a radioassay to monitor the hydrolysis of bead-bound 
peptides.18 Although this assay was used to assess the half-life of an amide bond in neutral water, 
which remarkably was determined to be approximately seven years, the authors suggested that 
this technique could also be used to monitor proteolysis. Meldal et. al. were the first to carry that 
idea forward with the development of an on-bead, combinatorial peptide library for assessing 
protease specificity.19 These combinatorial libraries were constructed through split peptide 
synthesis, leading to a single peptide sequence being present on each bead. The bead-conjugated 
peptides were constructed with a C-terminal fluorophore and N-terminal quencher, resulting in 
fluorescence quenching through Förster resonance energy transfer (FRET) prior to release of the 
fluorophore via proteolytic cleavage.20,21 Positions C-terminal and N-terminal to the site of 
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proteolytic cleavage are commonly referred to as prime (Pʹ) and nonprime (P) positions, 
respectively.22 Following treatment with a protease of interest, the fluorescent beads were 
isolated and subjected to Edman degradation where N-terminal residues are labeled and 
sequentially released to reconstruct the amino acid sequence. However, because each bead 
contained a mixture of intact and cleaved peptide, it was not possible to differentiate residues 
released from the native or neo-N-termini generated through proteolysis. This generally meant 
that the cleavage site needed to be predefined to accurately determine if amino acids detected 
during Edman degradation were from the intact or cleaved peptide. Once the ratio of intact to 
cleaved peptide was determined, this was used to calculate percent conversion and estimate 
catalytic efficiency.19 
 
Positional scanning substrate libraries 
One of the more widely applied, fluorescence-based techniques for analysis of protease 
specificity involves the generation of positional scanning-synthetic combinatorial libraries (PS-
SCLs). PS-SCLs consist of distinct pools of peptides in which an amino acid in one position is 
fixed within each pool, while the other positions contain a mixture of amino acids. Initial PS-
SCLs were used to determine the P4-P2 specificity of proteases and incorporated a 7-amino-4-
methylcoumarin (AMC) fluorophore at the P1ʹ position (Figure 1A).23 These libraries were 
restricted to certain P1 residues, such as aspartic acid and lysine, because the SPPS protocol 
required attachment of the growing peptide chain to the solid support through the P1 amino acid 
side chain. The development of a bifunctional 7-amino-4-carbamoylmethylcoumarin (ACC) 
fluorophore, which can be directly attached to a solid support, enabled the development of PS-
SCLs with diversity at the P1 position (Figure 1).24,25 P1 diversity significantly increased the 
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number of proteases amenable to analysis through the PS-SCL approach. PS-SCLs have been 
used to profile the P4-P1 specificity of diverse proteases, including cysteine cathepsins,26 
kallikreins,27 caspases,28 and granzymes.29  
 Drag and co-workers recently reported the development of ACC positional scanning 
libraries incorporating up to 110 unnatural amino acids in the P1 to P4 positions.30,31 These 
extended libraries, termed hybrid combinatorial substrate libraries (HyCoSuL), were used to 
identify a neutrophil elastase substrate with the highest reported catalytic efficiency.30 The 
increased chemical space explored through HyCoSuL has also enabled the development of 
selective caspase substrates.31 Furthermore, a Counter Selection Substrate Library (CoSeSuL) 
approach against caspases has been used to develop highly selective legumain probes.32 
 PS-SCLs have also been designed to profile prime side specificity through the 
incorporation of FRET-based quenching.33–38 FRET-based PS-SCLs contain a fluorophore and 
quencher separated by several amino acids. Unlike AMC- and ACC-based PS-SCLs, 
fluorescence occurs following proteolytic cleavage between any of the amino acids in the peptide 
substrate. Therefore, mass spectrometry is required to validate the site of cleavage and 
reconstruct a specificity profile. Recently, Poreba et. al. combined FRET and non-FRET based 
approaches to determine the optimal nonprime and prime side specificity of serine, cysteine and 
metalloproteases.39 
 
Electrophile-based libraries 
An alternative design for positional scanning libraries incorporates electrophilic ‘warheads’ that 
have been widely used for activity-based profiling of enzymes.40,41 The electrophile is placed at 
the P1 position and covalently labels the active-site nucleophile of the target protease. 
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Electrophile-based libraries contain diversity in the P4-P2 positions and generally use a 
radiolabel for quantitation of protease labeling.42,43 These libraries have been successfully used 
to profile a number of proteases, including cysteine cathepsins, calpains,42 and the proteasome 
subunits.43 Electrophile-based libraries are currently limited to cysteine, serine, and threonine 
proteases because of the requirement of an active site nucleophile and cannot be used to 
determine nonprime side specificity. However, a unique advantage of these libraries is that they 
can be readily converted into protease inhibitors, as specificity information is determined in the 
context of the electrophilic warhead that can be used in an inhibitor. Although beyond the scope 
of this review, large libraries of electrophile containing compounds and fragments have been 
applied for identifying PTM enzyme inhibitors.44,45  
 
Microarray peptide libraries 
Fluorescent peptide libraries are also commonly used in microarray formats to profile protease 
substrate specificity.46,47 Peptide microarrays consist of fluorescent substrates that are spatially 
separated on a microarray surface either by direct covalent attachment or through individual 
nanodroplets.46,48,49 Unlike PS-SCLs, which use pools of fluorescent substrates, cleavage of 
individual substrate sequences can be directly assessed with microarrays. This enables the highly 
multiplexed determination of kinetic parameters for each of the typically hundreds of substrates 
that are evaluated in a given experiment. Moreover, proteases often exhibit subsite cooperativity 
due to shared determinants of substrate specificity among binding pockets and the optimal 
positioning of amino acids within the target sequence. Such subsite cooperativity information is 
lost when using techniques that rely on pools of substrates, but is readily assessable with 
microarrays because of the spatial separation of individual substrates. One drawback of the 
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peptide microarrays developed to date is the relatively low sequence diversity as compared to 
positional scanning methods. With a few notable exceptions,50 peptide microarrays have been 
most successful when exploring nonprime specificity and other methods are required in order to 
query prime side specificity. 
  
Mixture-based oriented peptide libraries 
Edman degradation of mixture-based oriented peptide libraries has been used to determine both 
prime side and nonprime side protease specificity within the same assay format. This profiling 
strategy developed by Turk et. al. uses two separate peptide libraries.51 First, a fully randomized 
12-mer peptide library is synthesized with acetylated N-termini. This library is partially degraded 
with a protease of interest, releasing C-terminal cleavage products with free N-termini. Edman 
degradation of the C-terminal cleavage products is used to determine the frequency of each 
amino acid at each of the prime side positions. A second 12-mer peptide library is then 
synthesized that incorporates a randomized N-terminal 6-mer and the most favorable P1ʹ to P6ʹ 
amino acids for the C-terminal portion. The predefined prime side sequence directs cleavage to 
the middle of each peptide in the library. All peptides also contain a C-terminal biotin and free 
N-termini. Following protease treatment, C-terminal cleavage products are removed with 
immobilized avidin and the remaining N-terminal products are sequenced by Edman degradation 
to determine the nonprime side specificity.  This approach has been successfully applied to a 
range of proteases, including matrix metalloproteases,51,52 anthrax lethal factor,53 and the serine 
proteases HtrA1/2.54,55 Although this is a highly versatile technique, one limitation is that new 
peptide libraries generally need to be synthesized for each investigated protease. Furthermore, 
these libraries work best for proteases that have strong prime side specificity determinants, as a 
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sequence is required to direct cleavage to the middle of each peptide in the second peptide 
library. 
 
1.4 Multiplex Substrate Profiling by Mass Spectrometry 
Mass spectrometry in combination with proteome-derived substrate libraries has been 
successfully applied to define protease specificity.56–61 These “degradomics” methods use liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) to identify the site of proteolytic 
cleavage within proteome-derived peptides and can define prime side and nonprime side 
specificity determinants in a single assay. These techniques are quite powerful, but require 
chemical labeling steps for enrichment and identification of neo-termini and present a challenge 
in extracting kinetic parameters.  
MSP-MS was developed to provide simple, yet highly sensitive and quantitative assay for 
assessing the extended substrate specificity of proteases.  This technique currently uses a library 
of 228 synthetic tetradecapeptides that contain maximal physicochemical diversity within a 
minimal sequence space.62,63 This library was designed based on the observation that most 
proteases require two optimally positioned amino acids for substrate recognition and cleavage. 
This phenomenon is generally referred to as the “two-site hypothesis.” For example, the 
specificity of granzyme B is dominated by a preference for isoleucine at the P4 position and 
aspartic acid at the P1 position.24,62 As is evident in the crystal structure of granzyme B, two 
prominent cavities on the enzyme surface (S1 and S4) accommodate these residues and are the 
primary determinants of substrate recognition (Figure 2).64 Though these sites are not the only 
determinants of enzyme efficiency, they contribute to greater than 70% of the binding energy 
required for substrate recognition and turnover. Numerous proteases appear to follow the two-
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site hypothesis with the sites being juxtaposed, for example, on either side of the scissile bond or 
separated in space along the substrate by one or two amino acids. Therefore, physicochemical 
diversity in the MSP-MS library was generated through incorporation of all neighbor (XY) and 
near-neighbor (X*Y, X**Y) amino acid pairings. This simple and chemically defined library 
enables facile extraction of kinetic parameters for each substrate and is readily amenable to 
profiling the specificity of purified proteases or complex biological samples without the need for 
enrichment strategies.  
For MSP-MS specificity determination, a recombinant protease or other biological 
sample of interest is incubated with the peptide library and aliquots are removed at multiple time 
points (Figure 3). Cleavage sites within library peptides are then identified through LC-MS/MS 
analysis of each time point and specificity is visualized using a sequence logo, which displays 
protease amino acid preference relative to the site of cleavage. Label-free quantitation of both 
parent peptides and their corresponding cleavage products over time can be used to determine 
kinetic parameters for substrate hydrolysis. This information is critical for the prioritization of 
optimal sequences for substrate and inhibitor design.  
 Substrate specificities of a wide range of proteases from all major classes have been 
interrogated using the MSP-MS assay. Furthermore, because the termini of the peptides are 
unmodified, the library is well suited for profiling exopeptidase specificity. In particular, the 
MSP-MS assay has been used to profile carboxypeptidases, such as PRCP,62 which are generally 
not amenable to analysis with most of the previously discussed methods that use peptides 
modified with reporter groups. Furthermore, the MSP-MS assay has been used to identify the 
prime side specificity determinants of aminopeptidases, such as aminopeptidase N.65 
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 The ability of the MSP-MS library to readily profile mixtures of proteases has 
transformed our ability to quantitatively characterize proteolytic activity in complex biological 
systems. The assay was recently used to profile the catalytic subunits of the Plasmodium 
falciparum proteasome.66 The specificity differences between this and the human proteasome 
were then used to rationally design selective peptidic inhibitors that attenuated malaria 
development in vivo. The MSP-MS assay has been used with protease inhibitors, gene deletions, 
and immunodepletion in combination with traditional proteomic methods to identify component 
proteases that are highly active in complex biological samples. This has enabled the 
“deconvolution” of proteolytic signatures from fungal pathogens,63,67,68 parasitic organisms,69,70 
cancer cell lines,62,71 and patient samples,72,73 and allowed for the prioritization of proteases 
based on their functional contribution to the global substrate specificity profile. For example, the 
MSP-MS assay was used to analyze the global activity signatures of the opportunistic fungal 
pathogen Candida albicans in the planktonic and biofilm states.67 Comparison of the activity 
signatures from each state coupled to inhibitor and proteomic analysis revealed that two specific 
secreted aspartyl proteases (Saps) are upregulated during biofilm growth and are critical to 
biofilm formation in vitro and in vivo. MSP-MS was also recently used to identify two human 
aspartyl proteases that are selectively upregulated in cystic precursor lesions of pancreatic 
cancer.73 This strategy enabled the development of a highly accurate diagnostic assay using 
fluorogenic substrates for differentiating benign and premalignant lesions within a cohort of 
patient cyst fluid samples.  
  
1.5 Kinase specificity analysis using peptide library-based methods 
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The MSP-MS assay was designed and validated using proteases primarily because they cleave 
linear peptides and predominately rely on primary amino acid sequence for substrate recognition. 
Similarly, kinases typically phosphorylate unstructured regions of proteins, and their specificity 
is strongly dependent upon the amino acid residues surrounding the phosphoacceptor site.74 
Available crystal structures of eukaryotic kinases reveal that many kinases, as with proteases, 
bind their substrates in an extended, linear conformation.75,76 Computational efforts using these 
crystal structures have been able to successfully identify endogenous substrates, highlighting the 
importance of linear peptide sequences in kinase substrate specificity.77  
 There are numerous peptide-based approaches for profiling the substrate specificity of 
kinases.77–82 These methods primarily employ fluorescence, radioactivity, or colorimetry to 
detect enzyme activity. For kinase-directed PS-SCLs, a series of biotinylated peptides are 
generated. The central phosphorylatable residue remains fixed and all other positions are varied 
to query amino acid preferences.77 These peptide libraries are assayed in a multi-well format 
with the kinase of interest and radiolabeled ATP. Aliquots of the reaction are then transferred to 
a streptavidin-coated membrane, and phosphorylation of each peptide substrate is measured via 
radiography.83 Quantification of the amount of phosphorylation is then used to determine the 
specificity of the kinase of interest.  
 The MSP-MS assay presents a significant improvement upon traditional methods 
available for profiling kinases. Reporter groups used in other techniques can interfere with 
kinase-substrate recognition and radioactivity-based methods have costly disposal and present 
health hazards. The label-free and unbiased design of the MSP-MS library has made it applicable 
to the analysis of a wide variety of kinases.84 
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 Kinases without previously known substrate preference have been profiled using MSP-
MS, allowing for the discovery of their key substrate specificity determinants. In addition, the 
high sensitivity of this assay can allow for profiling of picomolar amounts of kinase.84 This 
enables the profiling of a kinase from a single immunoprecipitation experiment, which is highly 
advantageous if the enzyme cannot be readily expressed and purified. The MSP-MS assay has 
also been used to obtain kinetic parameters for phosphorylation of individual peptides within the 
library. This capability has proven useful for analyzing the effect of interacting factors on kinase 
substrate specificity and catalytic efficiency. For example, MSP-MS was recently used to 
interrogate the P-TEFb – HIV-1 Tat interaction. P-TEFb, a human kinase that is integral to Tat’s 
transactivation, phosphorylates RNA Polymerase II and two negative elongation factors in order 
to overcome the stalled RNA Pol II complex, which then allows transcription of the integrated 
viral genome to continue. There is controversy as to which site within RNA Pol II that P-TEFb 
phosphorylates, as well as what effect Tat has on specificity and phosphorylation rate.85–87 MSP-
MS analysis of recombinant and immunoprecipitated P-TEFb revealed that P-TEFb 
phosphorylates serine 5 within the RNA Pol II C-terminal domain. Analysis of P-TEFb with the 
addition of Tat revealed that Tat selectively increased the catalytic efficiency of P-TEFb toward 
peptides that most closely resembled RNA Pol II serine 5.84 
 
1.6 MSP-MS analysis of additional PTM enzymes 
There are approximately 200 types of PTM enzymes, and many of these enzymes have yet to be 
characterized.1 In addition to being able to detect proteolytic cleavage and phosphorylation 
events, the MSP-MS assay could allow for profiling of a variety of other PTMs (Figure 4A). The 
mass spectrometry-based detection strategy enables high adaptability because most peptide 
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modifications can be readily identified using existing MS data analysis packages. As described, 
this technology is particularly well suited for the specificity analysis of PTM enzymes that 
recognize peptide substrates in an extended, linear conformation. For example, crystal structures 
of the kinase CDK2/cyclin A and the histone acetyltransferase HAT1 bound to peptide substrates 
revealed that substrates adopt a linear conformation in the enzyme active site (Figure 4B-C).88,89 
Initial MSP-MS experiments with other types of PTM enzymes have already been carried out. O-
GlcNAc transferase (OGT) was profiled using the MSP-MS assay, resulting in “HexNAc” 
modifications at serine and threonine residues on five library peptides (unpublished data). 
Protein arginine N-methyltransferase (PRMT1), an arginine-specific histone methyltransferase, 
was also assayed using the MSP-MS library. PRMT1 methylated a single peptide in the library at 
an arginine residue adjacent to a glycine. This “RG” motif aligns with the known PRMT1 
substrate motif,  “RGG.”90 These preliminary results underscore that a simplified library of linear 
peptides can be used to obtain relevant PTM specificity information. 
 
1.7 Conclusion  
Peptide-based technologies have significantly expanded our ability to profile the substrate 
specificity of proteases and other PTM enzymes. The technologies discussed in this review can 
provide complementary information when applied together, enabling a more complete 
understanding of the specificity of a particular enzyme. The specificity information discovered 
can be used for a number of important applications. As mentioned previously, PTM enzyme 
specificity has facilitated the design of highly selective chemical probes, such as protease 
inhibitors or fluorescent substrates.30,66 These types of probes have been particularly useful in 
enabling the noninvasive detection of a variety of cancers.91,92 Specificity information can also 
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be used to help better define the biological roles of a given PTM enzyme. For example, PTM 
enzyme specificity has been used to identify the likely site of post-translational modification 
within endogenous substrates.16,17,93 This is particularly important when used in combination 
with degradomic-based methods or other techniques that identify large potential substrate 
repertoires. More generally, it is increasingly recognized that PTM enzymes, and particularly 
proteases, regulate biological systems through large, interconnected enzyme-inhibitor 
networks.94–96 Determining specificity is a critical aspect of identifying likely interaction partners 
within the context of these networks. This, in turn, helps to define novel enzymatic cascades, 
allowing for the development of a systems-level understanding of PTM enzyme biology. 
 Peptide-based enzyme profiling technologies have progressed significantly since the 
advent of SPPS and we expect that they will continue to be critical for improving our 
understanding of the vast repertoire of cellular functions that PTM enzymes regulate. 
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1.9 Figures and tables 
 
Figure 1.1. Construction of positional scanning-synthetic combinatorial libraries for 
analysis of prime side specificity. (A) During solid-phase peptide synthesis, 7-amino-4-
methylcoumarin (AMC) based positional scanning-synthetic combinatorial libraries are generally 
conjugated to the solid support via the side chain of the P1 amino acid, while 7-amino-4-
carbamoylmethylcoumarin (ACC) based libraries are conjugated directly through the 
fluorophore. (B) The four Pn sublibraries each contain 20 distinct pools of substrates, where one 
amino acid is fixed at Pn position and the remaining positions (X) contain an equimolar mixture 
of amino acids. 
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Figure 1.2. The ecotin peptide (purple) binds to the active site of granzyme B in a linear 
conformation.64 The catalytic triad is shown in red. Recognition of the peptide, IEPD (written 
P4-P1), is dominated by the S4 and S1 pockets (circled in yellow). 
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Figure 1.3. MSP-MS workflow for protease specificity determination. Either a recombinant 
protease, patient sample, conditioned media or other complex, protease-containing biological 
sample is added to the MSP-MS peptide library. Aliquots are removed at specific time points and 
peptide cleavage is assessed through LC-MS/MS analysis. Cleavage-site identification can be 
used to construct a sequence logo representation of the global substrate specificity. Cleavage 
product quantification enables the kinetic analysis of individual substrate cleavage events.  
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Figure 1.4. Application of the MSP-MS library to other PTM enzymes. (A) A general 
scheme for the specificity analysis of PTM enzymes using the MSP-MS assay. PTM enzymes 
are incubated with the peptide library and modification is detected through LC-MS/MS analysis. 
(B) The kinase CDK2/cyclin A (shown in blue) recognizes a peptide substrate (depicted as green 
sticks) in a linear conformation.89 The active site lysine residue is colored red. (C) Similarly, the 
histone acetyltransferase HAT1 also binds a linear substrate.88 
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Tables 
Table 1.1. Peptide-based protease activity profiling technologies.  
Peptide-based profiling 
technology Advantages Disadvantages 
On-bead FRET libraries 
High sequence diversity. 
Useful for analysis of subsite 
cooperativity. 
Requires prior knowledge of specificity. 
On-bead immobilization can produce 
artifacts. 
New libraries need to be synthesized 
for each protease. 
Positional scanning-
synthetic combinatorial 
libraries 
High sequence diversity, especially 
for newer libraries incorporating 
unnatural amino acids.  
Simple and validated in-solution 
fluorescent assay. 
Generally limited to nonprime specificity 
profiling.  
Does not provide information related to 
subsite cooperativity. 
Electrophile-based 
libraries 
High sequence diversity. 
Already contain electrophilic warhead 
for conversion into protease inhibitor. 
Generally limited to nonprime specificity 
profiling. 
Primarily limited to serine, threonine, 
and cysteine proteases. 
Peptide microarrays 
Can be used to determine kinetic 
parameters for substrate hydrolysis.  
Able to analyze protease activity in 
complex biological samples.  
Useful for analysis of subsite 
cooperativity. 
Limited sequence diversity.  
Immobilization of peptide substrates 
can produce artifacts.  
Limited to nonprime specificity profiling. 
Mixture-based oriented 
peptide libraries 
High sequence diversity.  
Can be used to profile prime and 
nonprime specificity. 
New libraries often need to be 
synthesized for nonprime side profiling.  
Primarily limited to proteases with 
strong prime side specificity.  
Requires enrichment step.  
Multiplex substrate 
profiling by mass 
spectrometry 
Can profile prime and nonprime 
specificity.  
Can be used to determine kinetic 
parameters for hydrolysis of 
substrates.  
Useful for analysis of subsite 
cooperativity.  
Global activity in complex samples 
can be analyzed.  
Rationally designed peptide library. 
Relativity limited sequence diversity.  
Activity is not monitored in real-time. 
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Chapter 2. Procathepsin E is highly abundant but minimally active in pancreatic ductal 
adenocarcinoma tumors 
 
2.1 Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related death in 
the United States. To improve patient outcomes for this lethal cancer, there has been a significant 
effort to improve our understanding of the molecular processes underlying malignant 
progression. The cathepsin family of lysosomal proteases is being increasingly recognized for 
their altered expression in PDAC and role in facilitating cancer progression. The aspartyl 
protease cathepsin E is overexpressed in a number of cancers and has been investigated as a 
biomarker for PDAC. Using a mass spectrometry based substrate-profiling assay, we previously 
identified cathepsin E as the dominant protease activity in conditioned media from a mouse 
PDAC cell line (O’Donoghue et al., 2012). In this study, we show that this PDAC cell line 
overexpresses cathepsin E over 400-fold and secretes the protease as a zymogen. By decreasing 
the pH, we induce removal of the cathepsin E prodomain and activate proteolysis. In a PDAC 
genetic model, we detect cathepsin E in precursor lesions and observe protein accumulation over 
the course of disease progression with cathepsin E accounting for more than 3% of the total 
protein in mice with end-stage disease. Cathepsin E again only exists in its proform and 
treatment of PDAC mice with a cathepsin E inhibitor was unable to decrease tumor burden. 
Lastly, we used our multiplex substrate profiling by mass spectrometry (MSP-MS) assay to 
identify two peptides that are hydrolyzed by procathepsin E at pH 6.5 and quantified cleavage by 
HPLC. This work represents a comprehensive biochemical analysis of cathepsin E proteolytic 
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activity in PDAC and could facilitate the development of improved biomarkers for disease 
detection. 
 
2.2 Introduction 
With a mean survival rate of six months and five-year survival rate of less than 5%, 
PDAC remains one of the most lethal cancers (Costello et al., 2012). PDAC can be distinguished 
from other pancreatic and non-pancreatic malignancies by a characteristic set of mutations, 
including activation of the oncogene Kras, which occurs in 95% of cases (Hezel et al., 2006). 
Kras mutation is thought to initiate the formation of pre-invasive ductal lesions, known as 
pancreatic intraepithelial neoplasias (PanINs) (Morris et al., 2010). Successive mutations in the 
tumor suppressor genes Ink4a (90%), Trp53 (75%), and Smad4 (50%) cause PanINs to undergo 
graded histological progression and eventual transformation into PDAC (Hezel et al., 2006). 
Generation of mice harboring these signature genetic mutations has yielded models that closely 
recapitulate the histopathogenesis of the human disease. 
In cancer, dysregulation of protease activity can lead to degradation of the extracellular 
matrix and facilitate neoplastic progression (Mason and Joyce, 2011). Many studies have focused 
on the roles of matrix metalloproteases (MMPs) and serine proteases due to their localization on 
the exterior of the cell (Kessenbrock et al., 2010; Sevenich and Joyce, 2014). In PDAC, silencing 
of the metalloprotease ADAM17 markedly reduced invasiveness and migration of cancer cells 
(Ringel et al., 2006). Cysteine proteases of the papain subfamily, known as cysteine cathepsins, 
are being increasingly investigated for their role in cancer. These proteases are predominantly 
found within endolysosomal vesicles, but are upregulated and secreted by cancer cells and thus 
may play an intracellular and extracellular role in tumor progression (Mohamed and Sloane, 
	 35	
2006). Using a cysteine cathepsin inhibitor, Joyce and colleagues observed defects in tumor 
growth, invasion, and angiogenesis in a mouse model of pancreatic islet cell carcinoma (Joyce et 
al., 2004). This phenotype was not observed following treatment with a broad spectrum MMP 
inhibitor (Bergers et al., 1999). Further studies by the same group determined that deletion of 
cathepsins B, L, or S in this mouse model correlated with a reduction in tumor burden and 
invasion (Gocheva et al., 2006, 2010).  
Two catalytically distinct members of the cathepsin family are the aspartyl proteases, 
cathepsins D and E. Cathepsin D is a ubiquitously expressed lysosomal protease (Reid et al., 
1989). The proform of the enzyme is overexpressed and secreted by a number of cancer types 
(Beaujouin et al., 2010; Laurent-Matha et al., 2001). Secreted procathepsin D binds the cell 
surface and stimulates growth of breast, prostate and lung cancer cells in vitro and in vivo. 
Cathepsin E is an intracellular aspartyl protease found mainly in cells of the immune 
system, such as lymphocytes (Sakai et al., 1989), microglia (Nishioku et al., 2002), dendritic 
(Chain et al., 2005), and activated B cells (Burster et al., 2008). Unlike the highly homologous 
cathepsin D, its intracellular localization varies with cell type. Cathepsin E has been reported to 
reside in endosomes, the plasma membrane, the endoplasmic reticulum, and the Golgi apparatus 
(Sakai et al., 1989; Zaidi and Kalbacher, 2008). While the exact physiological role of cathepsin E 
has yet to be elucidated, some studies indicate that it plays a role in antigen processing via the 
MHC class II pathway. Cathepsin E knockout mice develop atopic dermatitis-like skin lesions 
with increased susceptibility to bacterial infection and accumulate lysosomal membrane 
sialoglycoproteins that result in a novel form of lysosomal storage disorder (Tsukuba et al., 2003, 
2006). Overexpression of cathepsin E has been found in gastric, cervical, lung, intestinal and 
pancreatic cancer (Cruz-Monserrate et al., 2012; Mota et al., 1997; Ullmann et al., 2004). 
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Cathepsin E detection in the urine of mice with intestinal adenomas was reported as a potential 
marker for disease progression, while strong expression of cathepsin E in tumors of patients with 
lung carcinomas correlates with increased survival (Ullmann et al., 2004). In the pancreas, 
cathepsin E is detectable in early PanIN lesions and accumulates as cells progress to PDAC 
(Buchholz et al., 2005). While detection of the protein in pancreatic juice of patients has been 
shown to be a promising diagnostic marker to distinguish PDAC from chronic pancreatitis, no 
functional studies have been performed to characterize the role of cathepsin E in cancer 
progression (Uno et al., 2000). 
 Our group previously identified multiple secreted proteases, including cathepsin E, from 
a mouse PDAC cell line (O’Donoghue et al., 2012). In addition, we determined that cathepsin E 
was the dominant proteolytic activity in conditioned media from this cell line when assayed at 
pH 5.2. Since cathepsin E is generally found intracellularly and is optimally active between pH 
3.5 and pH 4.5, we decided to investigate if this enzyme could function in the pericellular space 
near neutral pH, namely pH 6.5 (Yasuda et al., 1999). We performed a comprehensive 
biochemical analysis of cathepsin E activation in both a mouse PDAC cell line and in tumors 
from a PDAC genetic model. Cell line and tumor associated cathepsin E exclusively exists as a 
proenzyme and tumor growth was not slowed by treatment with an active site inhibitor. 
However, procathepsin E retains residual proteolytic activity as detected by our MSP-MS assay. 
 
2.3 Results 
Only procathepsin E exists in primary PDAC cells 
In a previous study, we detected complement factor B, carboxypeptidase E, and 
cathepsins E, B, and L in conditioned media from a primary PDAC cell line derived from a 
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mouse tumor (O’Donoghue et al., 2012). When this media was assayed at pH 5.2, cathepsin E 
activity was responsible for the majority of detected proteolysis. These studies were performed 
with a global and unbiased substrate-profiling assay that uses mass spectrometry to detect the 
proteolytic degradation of a synthetic peptide library (O’Donoghue et al., 2012). To uncover the 
functional role of this enzyme in PDAC, an in-depth biochemical analysis of PDAC derived 
cathepsin E was required.  
In this study, we used the PDAC cell line from our previous work. This cell line is 
derived from p48-Cre; KrasG12D; Trp53f/f mice, which develop PDAC that histologically mirrors 
the human disease (Nolan-Stevaux et al., 2009). Immunoblotting analysis confirmed that 
cathepsin E was present in conditioned media from this cell line (Figure 1A). As cathepsin E is 
generally found intracellularly, we first wanted to confirm that the protein found in the media 
was not simply the result of cellular lysis. To test this, we treated cells with brefeldin A, an 
inhibitor of the secretory pathway, and confirmed that cathepsin E was no longer present in the 
conditioned media. Interestingly, with an apparent molecular mass of 53 kDa, the secreted 
cathepsin E was larger than the 46 kDa protein that was previously observed in a mouse study of 
atopic dermatitis (Tsukuba et al., 2003). In addition, the molecular mass of the intracellular 
protein was lower than that of the extracellular protein, indicating that these enzymes were 
differentially post-translationally modified (Figure 1B). Mouse cathepsin E is synthesized as a 
397 amino acid protein, consisting of a 20 amino acid signal peptide, a 39 amino acid propeptide, 
and a 338 amino acid catalytic domain (Zaidi and Kalbacher, 2008). Cathepsin E also has two N-
linked glycosylation sites at asparagines 91 and 323. Like other aspartyl proteases, procathepsin 
E can auto-activate under acidic conditions resulting in the irreversible hydrolysis of the 
propeptide (Richter et al., 1998). To determine if the higher molecular weight extracellular 
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cathepsin E corresponded to the proform, conditioned media was exposed to acidic conditions. 
This resulted in conversion to a lower molecular weight protein of approximately 49 kDa (Figure 
1B). Surprisingly, intracellular cathepsin E at 50 kDa was also converted to a lower molecular 
weight form (46 kDa) following acid exposure, indicating that both intracellular and extracellular 
proteins exist in the proform. The intracellular 46 kDa protein is likely the same cathepsin E that 
was detected by Tsukuba and coworkers (Tsukuba et al., 2003). Treatment of procathepsin E 
with the deglycosylase enzymes, PNGaseF, resulted in a protein of the same molecular weight, 
indicating that the mass difference was due to alternative glycosylation. 
Sastradipura and coworkers have previously shown that procathepsin E is expressed in rat 
microglia cells and is rapidly converted to the mature enzyme (Sastradipura et al., 2002). 
Immunoelectron microscopy of these microglia cells showed that the enzyme was associated 
with dense endosome-like organelles. Since only procathepsin E was detected in PDAC cellular 
lysates, we wanted to investigate if intracellular localization might be restricting acid-mediated 
protease activation. Using immunofluorescence, procathepsin E was detected throughout the 
cytoplasm and colocalized with early endosomal antigen 1 (EEA1) (Figure 1C). Late endosomes 
have a pH less than 6.0 and autoactivation of procathepsin E to the mature form occurs between 
pH 3.0 and pH 6.0 (Cappiello et al., 2004; Rao-Naik et al., 1995). Therefore it is unlikely that 
procathepsin E proceeds into late endosomes since the mature enzyme is not detected in the 
whole cell lysate. Instead, procathepsin E remains in early endosomes or is trafficked outside of 
the cell.  
 
Acidification of tumor lysates activates cathepsin E 
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 We proceeded to further analyze cathepsin E in pancreatic tumors from p48-Cre; 
KrasG12D; Trp53f/f mice. Tumors isolated from 13-14 week old mice were lysed under non-
denaturing conditions and incubated at neutral or acidic pH for 15 minutes. Immunoblot analysis 
could only detect 50 kDa procathepsin E at neutral pH. Exposure to acid caused a shift in 
molecular weight to 46 kDa, which corresponds to removal of the cathepsin E prodomain and 
generation of the mature enzyme (Figure 2A). No mature cathepsin E was detected in non-acid 
treated tumor lysates. 
 As procathepsin E can be activated to the mature enzyme, we used an internally 
quenched fluorescent substrate to quantify the activity in tumor lysates. This substrate is 
selective for cathepsin E over cathepsin D and other acid-acting proteases (Yoshiyuki et al., 
2005). At pH 3.5, recombinant mouse cathepsin E rapidly hydrolyzed the internally quenched 
substrate, while no activity was detected at pH 7.4 (Figure 2B).  At neutral pH, low levels of 
proteolytic activity were detected in tumor extracts from 10 week old PDAC mice and from 
exocrine pancreatic tissue isolated from non-tumor bearing littermates. This low-level activity is 
likely due to non-specific cleavage by proteases that are optimally active at neutral pH. When 
these same protein extracts were assayed at pH 3.5, a 13- to 37-fold increase in activity was 
detected in the tumor lysates, but not in the pancreatic extracts from healthy littermate controls. 
It was unclear from these results if cathepsin E activity in tumor extracts was due to the lack of 
an endogenous protease inhibitor or an increase in cathepsin E expression. To address this 
concern, procathepsin E protein levels were assessed in pancreatic tissue lysates from PDAC 
mice and non-tumor bearing littermates. 
 
Procathepsin E is overexpressed in PDAC tumors 
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Procathepsin E was detected in all tumor extracts by immunoblot, but not in tissue from 
healthy littermates (Figure 2C). This suggests that malignant transformation in this mouse model 
is driving enhanced expression of this protein. Interestingly, immunoblot analysis failed to detect 
procathepsin E or mature cathepsin E in tumor lysate from the RIP1-Tag2 model of pancreatic 
islet carcinoma. The RIP1-Tag2 mouse model expresses the SV40 T antigen oncogenes in 
insulin-producing β cells and a number of prior studies have demonstrated that protease 
overexpression promotes tumorigenesis in this model (Folkman et al., 1989). In fact, the cysteine 
cathepsins H, L, C, Z, B and S genes were found to be upregulated during RIP1-Tag2 
tumorigenesis and these enzymes contributed to angiogenic switching, tumor vascularity, and 
proliferation (Joyce and Hanahan, 2004; Joyce et al., 2004). Using the same quantitative RT-
PCR approach as outlined in the RIP1-Tag2 mouse study, we compared cathepsin expression 
levels in PDAC tumors to healthy pancreatic tissue. Cathepsin E mRNA expression increased 
441-fold in tumors relative to healthy pancreatic tissue, while cathepsins B, H, S, and Z mRNA 
levels increased by 3-fold or less (Figure 2D). Cathepsin L, C and D expression levels were 
lower in tumors than in healthy pancreatic tissue. The high expression of cathepsin E relative to 
the other cathepsins prompted us to further investigate the role of this protease in promoting 
tumorigenesis in the p48-Cre; KrasG12D; Trp53f/f PDAC mouse model. More generally, this 
points to specific cathepsins playing unique roles in the development of different types of 
pancreatic tumors. 
 
Cathepsin E expression increases with progressive dysplasia 
As procathepsin E was present in PDAC tumors and not in healthy tissue, we investigated 
the time-dependent expression and localization of this protein in the pancreas of p48-Cre; 
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KrasG12D; Trp53f/f mice as they progress from harboring low-grade PanINs to invasive PDAC. 
Immunohistochemical staining of the exocrine pancreas of non-tumor bearing mice showed only 
basal levels of procathepsin E. However, by 4 weeks procathepsin E expression increased and 
the protein localized to neoplastic ductal structures. Staining intensity increased with progressive 
stages of dysplasia from 4 weeks to end-stage (Figure 3A-D). Mice succumb to the disease 
between 13-15 weeks and dense staining is evident in tumors from deceased mice. This 
unusually strong staining prompted us to quantity the amount of procathepsin E protein in PDAC 
tumor lysates using a semi-quantitative immunoblot. Surprisingly, approximately 6.25 
nanograms of procathepsin E were present in 0.2 µg of total protein extracted from PDAC tumor 
lysates (Figure 3E). Therefore, in end-stage mouse tumors, procathepsin E accounted for 
approximately 3% of the total soluble protein extracted from the tumor.  
 
Peptide inhibitors bind to procathepsin E 
Structural studies of aspartyl protease zymogens revealed that the propeptide occupies the 
enzyme active site. Upon acid exposure, structural rearrangements lead to cleavage and 
dissociation of the propeptide (Ostermann et al., 2004). At pH 7.5 we did not observe 
procathepsin E activity against a fluorescent substrate (Figure 2B), suggesting that the propeptide 
is restricting access to the protease active site. We were curious to determine if an inhibitor of 
cathepsin E could compete with the propeptide for binding to the active site.  Pepstatin is a 
potent inhibitor of cathepsin E and other pepsin-type aspartyl proteases (Dunn, 2002). We have 
successfully used pepstatin-agarose beads to enrich for aspartyl proteases from complex protein 
mixtures (Bibo-Verdugo et al., 2015). Using a similar approach, we added pepstatin-agarose 
beads to tumor lysate and then diluted the mixture in either pH 7.5 lysis buffer or pH 3.5 
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activation buffer. After 30 minutes incubation at pH 7.5 we were unable to recover procathepsin 
E. However, incubation at pH 3.5 in the presence of excess pepstatin-agarose led to recovery of 
procathepsin E and not the lower molecular weight mature protease (Figure 4A). This shows that 
the cathepsin E prodomain can be displaced prior to cleavage occurring, enabling access to the 
active site of the proenzyme. 
To target procathepsin E in PDAC, we used the FDA approved protease inhibitor, 
ritonavir. Ritonavir was approved to treat HIV and potently inhibits the viral aspartyl protease, 
however, it has nanomolar affinity towards cathepsin E (Kempf et al., 1998). Although it is 
likely that ritonavir has weaker affinity for procathepsin E we decided to treat Pdx-1-Cre; 
LSLKrasG12D; Trp53f/f mice with 125 mg/kg of for 28 days. After this period, tumors were 
removed and weighed. No significant difference in tumor burden was observed between ritonavir 
and vehicle treated animals (Figure 4B). There are a number of possibilities for why ritonavir 
failed to reduce tumor volume. PDAC tumors may be refractory to therapeutic intervention using 
this compound. Alternatively, procathepsin E may not play a critical enzymatic role in tumor 
progression and the use of a catalytic inhibitor will, therefore, not impact tumor progression. 
   
Procathepsin E retains minimal activity at pH 6.5 
Cruz-Monserrate and colleagues have shown that the PDAC tumor microenvironment is 
acidic and therefore it is possible that conditions exist within the tumor that facilitate 
procathepsin E activity, but are insufficient to promote auto-activation to the mature enzyme 
(Cruz-Monserrate et al., 2014). Our studies with pepstatin-agarose showed that the cathepsin E 
active site is accessible prior to prodomain cleavage. We were unable to detect cleavage using a 
standard cathepsin E fluorescent substrate, but other substrates may be able to compete with the 
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cathepsin E propeptide and allow us to detect activity. Therefore, we investigated procathepsin E 
activity and specificity using the highly sensitive MSP-MS assay. This assay uses tandem mass 
spectrometry to monitor proteolytic cleavage of 228 synthetic tetradecapeptides. At pH 5.5, 
procathepsin E was converted to the mature enzyme and 65 unique cleavages were detected 
following 15 minutes of incubation (Figure 5A, Supplementary Figure 1). The substrate 
specificity profile under these conditions was similar to what has been previously reported for 
cathepsin E (Impens et al., 2010; O’Donoghue et al., 2012). When we performed the same assay 
at pH 6.5, auto-activation of procathepsin E did not occur (Supplementary Figure 1). However, 
cleavage of two peptides – PHWQRVIFFRLNTP and KWLIHPTFSYnRWP – in the library was 
evident after 4 hours incubation (Figure 5B). The same peptides were also hydrolyzed by mature 
cathepsin E at pH 5.5 within 15 minutes. 
 The mass spectrometry based assay is largely qualitative and therefore we decided to use 
reversed-phase high performance liquid chromatography (RP-HPLC) to quantify the rate of 
hydrolysis. One of the peptide substrates is cleaved into two products that each contains a 
tryptophan residue, allowing for quantitation via tryptophan fluorescence during RP-HPLC 
analysis. At pH 5.5, 2 nM of mature cathepsin E completely cleaved 100 µM of substrate within 
1 hour (Supplementary Figure 2). The two cleavage products eluted from the C18 column 
between 15.25 and 16.25 minutes. Analysis of the mass of the cleavage products by MALDI-MS 
demonstrated that cathepsin E cut at the predicted site (Supplementary Figure 3). At pH 6.5, 
time-dependent product formation was evident using 200 nM of procathepsin E (Figure 5C). 
After 216 hours incubation, only 2.6% percent of the parent peptide was hydrolyzed.  
 
2.4 Discussion 
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Previous work by our group determined that a PDAC cell line isolated from a Pdx-1-Cre; 
LSLKrasG12D; Trp53f/f mouse secretes several endo-lysosomal proteases, such as cathepsin B, L, 
and E (O’Donoghue et al., 2012). Several studies have looked at the role of the cysteine 
cathepsins B and L in pancreatitis and pancreatic cancer (Gocheva et al., 2006; Lyo et al., 2012). 
In fact, these enzymes have been implicated in playing multiple roles in various cancers (Joyce 
and Hanahan, 2004; Sevenich et al., 2014). However, few studies have focused on the role of the 
aspartyl cathepsins in cancer, with the notable exception of cathepsin D in breast cancer (Masson 
et al., 2010). We were particularly intrigued to detect high levels of cathepsin E in conditioned 
media from PDAC cells and sought to investigate further the expression, localization, and 
enzymatic function of this enzyme. However, in this study we show that only procathepsin E is 
secreted from the primary cells in culture and activity is only detectable after the media becomes 
sufficiently acidic to induce protease auto-activation.  
A previous immunohistochemical study by Buchholz and colleagues demonstrated that 
human cathepsin E is absent from the normal pancreatic duct, but abundant in PDAC and 
precursor lesions (Buchholz et al., 2005). In agreement with this, we show that cathepsin E in the 
Pdx-1-Cre; LSLKrasG12D; Trp53f/f mouse model is hyperexpressed in PDAC tumors and 
accumulates in high abundance in the cytoplasm. In fact, it is likely to be one of the most 
abundant proteins in the mouse tumor extract and accounts for approximately 3% of the total 
soluble protein. This intracellular protein exists only as procathepsin E but can be activated upon 
brief exposure to acid. The absence of mature cathepsin E in the tumor lysate indicates that the 
protein does not traffic through the normal endo-lysosomal pathway with exposure to a 
sufficiently acidic environment to cause activation. Therefore, the accumulation of excess 
intracellular procathepsin E may indicate endo-lysosomal dysfunction in these cells.  
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The excess procathepsin E identified in PDAC is analogous to procathepsin D secreted 
by breast cancer cells (Laurent-Matha et al., 2001). Procathepsin D is secreted at low levels by 
normal mammary epithelial cells, but secretion increases by up to 40-fold in breast cancer cell 
lines. Several studies have shown that procathepsin D binds to prosaposin in the ER and these 
proteins are co-secreted (Gopalakrishnan et al., 2004; Laurent-Matha et al., 2002). In addition, 
procathepsin D can bind to cystatin-C and will degrade this protein upon activation to the mature 
enzyme at pH 3.5 (Laurent-Matha et al., 2012; Khalkhali-Ellis and Hendrix, 2015). Degradation 
of this macromolecular inhibitor ultimately results in an increase in cysteine protease activity, 
which promotes tumor progression and metastasis. A recent study showed that secretion of 
procathepsin D from the MCF-7 breast cancer cell line is increased under hypoxia (Achour et al., 
2016). Hypoxic tumors cause acidification of the tumor microenvironment and Cruz-Monserrate 
and colleagues demonstrated that an acidic microenvironment clearly exists within PDAC 
tumors (Cruz-Monserrate et al., 2014). Interestingly, the microenvironment conditions appear to 
favor the functioning of acid-acting proteases such as those found in the endosomes and 
lysosomes. However, it appears to be insufficiently acidic to activate procathepsin E in 
pancreatic tumors and procathepsin D in breast tumors. 
While procathepsin E may mediate its functions through binding partners, we decided to 
investigate if this protein was catalytically active under pH conditions that are relevant to the 
tumor. We show that the aspartyl protease inhibitor, pepstatin, can compete with the propeptide 
sequence for binding to the enzyme active site. This prompted us to treat mice with the HIV 
protease inhibitor ritonavir; however, no reduction in tumor burden was evident. While ritonavir 
is a potent inhibitor of the mature enzyme (Kempf et al., 1998), it is likely to be much less potent 
against the zymogen. Therefore, it was unclear if the ineffectiveness of the inhibitor was the 
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result of cathepsin E activity not being important for tumor progression or if the inhibitor was 
unable to sufficiently engage with the enzyme. 
Although it is well established that protease zymogens can be catalytically active, this has 
not been demonstrated for procathepsin E. Previous studies have shown that rat cathepsin E 
alters its substrate specificity at neutral pH and becomes more “trypsin-like”, cleaving on the C-
terminal side of arginine residues. However, Zaida and coworkers predicted that rat cathepsin E 
was likely to be contaminated with trace amounts of a “trypsin-like” proteases that are optimally 
active at neutral pH (Zaidi et al., 2007). Here we used mass spectrometry and a library of 228 
tetradecapeptides to detect proteolytic activity of procathepsin E (O’Donoghue et al., 2012). This 
highly sensitive assay identified two peptide substrates for procathepsin E that are also 
hydrolyzed by the mature enzyme. The cleavage site within these peptides mirrors the known 
specificity of cathepsin E. Taken together, these results show that procathepsin E has weak 
proteolytic activity at pH 6.5 and suggests that the highly abundant zymogen may play an 
enzymatic role in tumor progression.    
While our studies could not detect mature cathepsin E in whole tumor extracts, it is 
possible that a fraction of the 53 kDa procathepsin E gets converted to the 49 kDa mature form, 
but is undetectable by immunoblot. A number of imaging agents targeting cathepsin E activity 
have recently been developed to monitor PDAC status in vivo (Cruz-Monserrate et al., 2012; 
Keliher et al., 2013; Li et al., 2014). These imaging agents were designed to target the mature 
enzyme active site or be specifically cleaved by cathepsin E. In addition, Abd-Elgaliel and 
colleagues have developed a cathepsin E activated prodrug that is toxic to cells expressing 
cathepsin E (Abd-Elgaliel et al., 2013). From our work it is clear that in PDAC, cathepsin E 
primarily exists as a zymogen with minimal enzymatic activity. It is likely that developing 
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probes to target procathepsin E may therefore be more effective. For example, radiolabeled 
antibodies have been successfully used to image proteases that are overexpressed in tumors and 
could be developed against procathepsin E for non-invasive detection of PDAC (LeBeau et al., 
2013). 
In conclusion, our analysis of cathepsin E activation in PDAC revealed that the protease 
is highly overexpressed and exists exclusively in its proform. Cathepsin E may play a role in 
PDAC progression that is independent of proteolytic activity. Cathepsin E is now recognized as 
an exciting biomarker for PDAC and this information may facilitate the development of novel 
imaging agents for monitoring disease status. 
 
2.5 Materials and Methods 
Mouse strains, tissue culture, and ritonavir administration 
The p48-Cre; KrasG12D; Trp53f/f mouse strain was used and cells were isolated from 
PDAC tumors as previously described (Nolan-Stevaux et al., 2009). Cells were maintained in 
complete DMEM with 10% FBS. Mice were treated for 28 days with 125 mg/kg ritonavir or 
ethanol by oral gavage. The mouse pancreas was removed and weighed and tumor burden was 
assessed using the ratio of tumor weight to body weight. All animal studies were conducted in 
compliance with University of California Institutional Animal Care and Use Committee 
guidelines.  
 
Histological analysis, immunochemistry, and immunofluorescence 
Pancreatic tissue from p48-Cre; KrasG12D; Trp53f/f mice was harvested after 4 and 10 
weeks and from animals with end-stage disease. Tissue was fixed overnight in zinc-buffered 
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formalin and embedded in paraffin. 5 mm thick sections were subjected to either H&E staining 
or an antigen retrieval procedure (Citra; BioGenex). Following inhibition of endogenous 
peroxidases and blocking the slides, goat anti-mouse cathepsin E antibody (1:100; R&D Systems 
AF1130) was applied overnight at 4°C. Biotinylated or fluorochrome-conjugated antibodies were 
used as secondary antibodies (1:200; Jackson Immunoresearch). 3-39-DAB tetrahydrochloride 
(Sigma D4293) was used as a chromogen. 
 
Cathepsin E isolation and western blotting 
Mouse tumors and cell lines were lysed in 20mM Tris-HCl pH 7.5, 150mM NaCl, 1% 
Triton X-100 buffer. Protein lysates were diluted to 1.5 mg/ml in lysis buffer or 1.25 mM sodium 
acetate pH 3.5 and incubated on ice for 30 minutes.  Where appropriate, 20% (v/v) pepstatin-
agarose (Sigma) was added to protein lysates and incubated on ice for 30 minutes. Agarose beads 
were washed in lysis buffer or sodium acetate buffer and protein was eluted in 1X LDS sample 
buffer containing 20 mM TCEP solution (ThermoFisher Scientific). Secreted cathepsin E was 
isolated by immunoprecipitation with 2.5 µg of goat anti-mouse cathepsin E antibody (R&D 
Systems AF1130) attached to Protein G Dynabeads. All samples were subjected to 
electrophoresis on denaturing 10% NuPAGE Bis-Tris gels (Invitrogen). Proteins were 
transferred to polyvinylidene fluoride membranes and blocked in Tris buffered saline Triton X-
100 (TBST) containing 5% (w/v) milk. Membranes were incubated with a polyclonal rabbit anti-
mouse cathepsin E antibody (1:1,000; Thermo Scientific PA3-16821), washed and incubated 
with goat-derived HRP-conjugated secondary antibody (BioRad). Immunoblots were developed 
on film with the ECL Plus detection system (GE Healthcare). To verify that equal amounts of 
protein were being compared across samples, actin levels were quantified in parallel with an 
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anti-β-actin antibody (1:10,000; Sigma). Where indicated, samples were treated with the 
deglycosylase PNGaseF (New England Biolabs) according to the manufacturers protocol prior to 
gel electrophoreses. 
 
Fluorescent protease assays 
All assays were performed at room temperature in either PBS containing 0.1% Triton X-
100 or 50 mM sodium acetate, pH 3.5, 100 mM NaCl, 0.1% Triton X-100 using 40 µM substrate 
(Bachem M-2625). Assays were performed in triplicate in black round-bottom 96-well plates on 
a SpectraMax Gemini fluorescence spectrometer (Molecular Devices) using excitation and 
emission wavelengths of 328 nm and 393 nm, respectively.  
 
Quantitative PCR  
Total RNA was prepared from tumors and cell lines using the RNeasy Mini (Qiagen) 
according to the manufacturer’s recommendations. Total RNA from microdissected samples was 
prepared using the RNeasy Micro (Qiagen). DNase treatment and RNA cleanup were performed 
with the DNA-Free RNA Kit (Zymo Research). cDNA synthesis was performed using iScript 
(Bio-Rad). PCRs were performed using the following TaqMan assays (Applied Biosystems): 
Ctsb, Ctsc, Ctsh, Ctsl, Ctss, Ctsx, Ctsd, and Ctse. The mGus assay was obtained from Integrated 
DNA Technologies (F) CTCATCTGGAATTTCGCCGA; (R) GGCGAG 
TGAAGATCCCCTTC; (Probe) fam-CGAACCAGTCACCGCTGAGAGTAATCG-bhq1 was 
used to normalize expression. Quantitative PCR reactions were performed on an ABI7900HT 
Sequence Detection System. Ct values were determined and subtracted to obtain the ΔCt [ΔCt = 
Ct(test locus) - Ct(control locus)]. Relative fold difference was calculated as 100*2- ΔCt. 
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Multiplex peptide cleavage assay 
 Recombinant mouse cathepsin E proteolytic activity was analyzed using the MSP-MS 
assay as described previously (O’Donoghue et al., 2012). For all assays, an expanded 228 
peptide library was used and split into two pools containing 114 peptides at 500 nM each. Assays 
were performed at pH 6.5 for procathepsin E and pH 5.5 for mature cathepsin E. To promote 
proteolytic activity of procathepsin E, 250 nM of enzyme was incubated with peptide pools at 37 
°C. Mature cathepsin E was assayed at 50 nM. Aliquots were removed and acid-quenched to pH 
2 or less with formic acid after 15, 60, 240, and 1200 minutes. To avoid acid-mediated activation 
of cathepsin E, 10 µM of the aspartyl protease inhibitor pepstatin A (Sigma) was added to assays 
directly before the acid-quench. Control samples without recombinant cathepsin E were prepared 
under identical conditions to account for non-enzymatic degradation of the substrates. Prior to 
LC-MS/MS peptide sequencing, samples were desalted using C18 ZipTips (Millipore). 
 For LC-MS/MS, an LTQ Orbitrap XL mass spectrometer (Thermo) equipped with a 
10,000 psi system nanoACQUITY UPLC instrument (Waters) was used for reversed phase 
chromatography with a C18 column (1.7 µm bead size, 100 µm x 100 mm). The LC was 
operated at 600 nL/min flow rate and peptides were separated using a linear gradient over 65 
minutes from 2% B to 30% B, with solvent A being 0.1% formic acid in water and solvent B 
being 0.1% formic acid in 70% acetonitrile. Survey scans were recorded over 350-1800 m/z 
range and MS/MS was performed with CID fragmentation on the six most intense precursor 
ions. Mass spectrometry peak lists were generated using in-house software called PAVA. Peak 
lists were searched in Protein Prospector v. 5.10.0 against a database containing the 228 peptide 
sequences from the MSP-MS library. For database searching, peptide sequences were allowed to 
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contain the following variable modifications: oxidation of tryptophan, proline, and phenylalanine 
and N-terminal pyroglutamic acid from glutamine or glutamic acid. Cleavage site data was 
extracted from Protein Prospector using the MSP-extractor software. iceLogo software was used 
to visualize conserved patterns in amino acid sequence at ±4 positions adjacent to the identified 
site of cleavage (Colaert et al., 2009). 
 
Analysis of cathepsin E activity by HPLC 
 Activity assays with recombinant cathepsin E and individual substrates were performed 
in pH 6.5 PBS and pH 5.5 sodium acetate buffer. For pH 6.5 assays, 250 nM of cathepsin E was 
incubated with 100 µM substrate at 37 °C. After 4, 8, 24, 72, and 216 hours, protease activity 
was heat inactivated. For pH 5.5 assays, 2 nM of cathepsin E was incubated with 100 µM 
substrate at 37 °C. Cathepsin E was heat inactivated after 2 and 60 minutes incubation. All 
samples were compared to a control containing 100 µM substrate and no enzyme. Following heat 
inactivation, digestion products were analyzed using a 1100 HPLC system (Agilent) with a C18 
column (10 µm bead size, 4.6 mm x 250 mm, Vydac). The HPLC was operated at a flow rate of 
1 mL/min with solvent A: 0.1% trifluoroacetic acid in water and solvent B: 0.1% trifluoroacetic 
acid in 95% acetonitrile. A linear gradient from 5% B to 95% B over 17 minutes was used for 
peptide separation. Tryptophan fluorescence with excitation at 280 nM and emission at 330 nM 
was used for detection of the full-length substrate and cleavage products. For quantification of 
substrate conversion, peak heights were compared between samples and controls. 
 
Peptide cleavage site confirmation by mass spectrometry 
	 52	
 Cleavage sites within individual peptides were identified by matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS). 0.5 µL of reaction mixtures were mixed 
with 0.5 µL of α-Cyano-4-hydroxycinnamic acid (CHCA) matrix and spotted on a MALDI plate. 
Spectra were then acquired over a mass range of 500-2,500 Daltons using an Axima 
Performance MALDI-time-of-flight/time-of-flight (TOF/TOF) mass spectrometer (Shimadzu). 
An average of 200 shots was used for each spectra. All spectra were analyzed using the 
Shimadzu Biotech Launchpad. 
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2.7 Figures 
 
 
Figure 2.1 Expression and localization of cathepsin E in a mouse PDAC cell line. (A) Western 
blot analysis of cathepsin E in conditioned media with and without brefeldin A treatment. Size 
markers correspond to kilodaltons (kDa). (B) Western blot analysis of cathepsin E in the cell 
lysate and conditioned media treated with acid and the deglycosylase PNGaseF. (C) 
Immunofluorescence of cathepsin E and the endosomal marker EEA1. DAPI is shown in blue.
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Figure 2.2 Cathepsin E expression and activity in mouse PDAC tumors. (A) Western blot 
analysis of cathepsin E from three tumors before and after acid treatment. (B) Cathepsin E 
activity in tumors and pancreatic tissue from wild type (WT) littermates. Cleavage velocity is 
given in relative fluorescence units per second (RFU/sec). (C) Immunoblot analysis of cathepsin 
E expression in pancreatic tissue from WT, p48-Cre; KrasG12D; Trp53f/f, and RIP1-Tag2 mice. 
(D) Quantitative PCR analysis of cathepsin mRNA levels in pancreatic tissue from WT and 
PDAC animals. GUS mRNA levels were used for normalization. 
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Figure 2.3 Immunohistochemical staining of cathepsin E in pancreatic tissue from p48-Cre; 
KrasG12D; Trp53f/f  mice after (A) 4 weeks, (B) 10 weeks, (C) and in end-stage (D) and WT mice. 
(E) Semi-quantitative western blot analysis of cathepsin E from tumor lysate of end-stage mice. 
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Figure 2.4 Cathepsin E inhibitor binding in tumor lysate and inhibition in PDAC mice. (A) 
Affinity purification (AP) of cathepsin E from PDAC tumors using pepstatin-agarose beads 
followed by western blot analysis. Acid treatment was required for affinity purification of 
cathepsin E. (B) Effect of ritonavir treatment on tumor burden in PDAC mice. 
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Figure 2.5 Analysis of procathepsin E activity. (A) iceLogo generated from the cathepsin E 
cleavage events detected after 15 minutes using the MSP-MS assay. To profile mature cathepsin 
E the MSP-MS assay was performed at pH 5.5. In the iceLogo n corresponds to norleucine. (B) 
The cleavage sites within two peptides by mature cathepsin E (pH 5.5 – blue) and procathepsin E 
(pH 6.5 – red). The time at which cleavage was first observed is shown above the arrows 
indicating the site of cathepsin E cleavage. (C) HPLC chromatograms of peptide cleavage 
products, which have amino acid sequences shown above each peak, following incubation with 
procathepsin E (pH 6.5 – red) and mature cathepsin E (pH 5.5 – black). Abundance of cleavage 
products was monitored using tryptophan fluorescence with excitation at 280 nm and emission at 
330 nm. 
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Supplementary Figure 2.1 Cathepsin E activation. Western blot analysis of recombinant 
cathepsin E incubated for up to 1200 minutes in pH 5.5 or pH 6.5 acetate buffer. 
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Supplementary Figure 2.2 Peptide cleavage by mature cathepsin E. Peptide HPLC 
chromatogram when incubated for one hour in pH 5.5 acetate buffer (gray) or with 2 nM 
cathepsin E in pH 5.5 acetate buffer (black). Cleavage products and parent peptide abundance 
were quantified using tryptophan fluorescence with excitation at 280 nm and emission at 330 
nm.  
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Supplementary Figure 2.3 Identification of peptide cleavage site by MALDI-MS. (A) One hour 
incubation in pH 5.5 acetate buffer. (B) One hour incubation in pH 5.5 acetate buffer with 2 nM 
cathepsin E.  	
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Chapter 3. Global protease activity profiling provides differential diagnosis of pancreatic 
cysts 
 
3.1 Translational relevance: With advances in abdominal imaging technologies, the incidental 
detection of pancreatic cysts continues to rise. However, there remains a lack of accurate 
molecular diagnostics for differentiating benign cystic lesions from those that can progress into 
pancreatic cancer. This has led to a dramatic increase in the number of potentially unnecessary 
pancreatic resections, which are associated with high rates of morbidity. Using a global and 
unbiased protease-activity profiling approach and patient cyst fluid, we determined that the 
activities of the aspartyl proteases gastricsin and cathepsin E accurately differentiate 
premalignant mucinous cysts from benign nonmucinous cysts. In particular, analysis of 
gastricsin activity demonstrated 93% sensitivity and 100% specificity for differentiating 
mucinous lesions. Our simple and direct fluorescence-based approach for stratification of 
pancreatic cysts significantly outperformed the most widely used molecular biomarker – 
carcinoembryonic antigen (CEA) – and can be readily translated into an actionable diagnostic 
assay to help improve clinical management of these challenging lesions. 
 
3.2 Abstract 
Purpose: Pancreatic cysts are estimated to be present 2-3% of the adult population. 
Unfortunately, current diagnostics do not accurately distinguish benign cysts from those that can 
progress into invasive cancer. Missregulated pericellular proteolysis is a hallmark of malignancy, 
and therefore, we used a global approach to discover protease activities that differentiate benign 
nonmucinous cysts from premalignant mucinous cysts.  
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Experimental Design: We employed an unbiased and global protease profiling approach to 
discover protease activities in 23 cyst fluid samples. The distinguishing activities of select 
proteases was confirmed in 110 samples using specific fluorogenic substrates and required less 
than 5 µL of cyst fluid. 
Results: We determined that the activities of the aspartyl proteases gastricsin and cathepsin E are 
highly increased in fluid from mucinous cysts. Immunohistochemical analysis revealed that 
gastricsin expression was associated with regions of low-grade dysplasia, whereas cathepsin E 
expression was independent of dysplasia grade. Gastricsin activity differentiated mucinous from 
nonmucinous cysts with a specificity of 100% and a sensitivity of 93%, whereas cathepsin E 
activity was 92% specific and 70% sensitive. Gastricsin significantly outperformed the most 
widely used molecular biomarker, carcinoembryonic antigen (CEA), which demonstrated 94% 
specificity and 65% sensitivity. Combined analysis of gastricsin and CEA resulted in a near 
perfect classifier with 100% specificity and 98% sensitivity.  
Conclusions: Quantitation of gastricsin and cathepsin E activities accurately distinguished 
mucinous from nonmucinous pancreatic cysts and has the potential to replace current diagnostics 
for analysis of these highly prevalent lesions. 
 
3.3 Introduction 
The detection of pancreatic cysts has increased dramatically due to the rising use of high-
resolution abdominal imaging. Pancreatic cysts are incidentally detected in 13-45% of patients 
evaluated by magnetic resonance imaging and 2% of patients evaluated by computed 
tomography (1–3). The most frequently detected pancreatic cysts include intraductal papillary 
mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs), pseudocysts, and serous 
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cystadenomas (SCAs) (4). Both IPMNs and MCNs, which are collectively referred to as 
mucinous cysts, may develop foci of high-grade dysplasia or cancer (5). At the time of resection, 
~30% of IPMNs and ~15% of MCNs contain invasive cancer (6,7). Pseudocysts and SCAs, 
which are both nonmucinous, rarely undergo malignant degeneration and are considered benign 
lesions that typically do not require resection or continued surveillance. Clinical decision making 
for pancreatic cysts relies largely on radiographic and clinical features, augmented by analysis of 
cyst fluid collected by endoscopic ultrasound with fine needle need aspiration (EUS-FNA) (8). 
Unfortunately, with current clinical guidelines, distinguishing nonmucinous from mucinous cysts 
remains a challenge. The preoperative diagnosis of mucinous cysts is incorrect in up to 30% of 
cases and benign cysts are often resected, exposing patients to an unnecessary risk for morbidity 
(9–12). 
 As abdominal imaging remains unable to accurately differentiate pancreatic cyst types, 
there has been considerable effort towards developing improved diagnostic biomarkers. Most of 
these biomarkers utilize cyst fluid collected by EUS-FNA. CEA is the most widely investigated 
biomarker and is 60-80% accurate for differentiating mucinous from nonmucinous cysts (13,14). 
KRAS mutations occur in more than 90% of pancreatic cancers and are frequently observed in 
mucinous cysts (15,16). Analysis of cyst fluid DNA revealed that KRAS mutations are 100% 
specific, but only 50% sensitive for diagnosing a mucinous cyst (17). Similarly, analysis of 
mutations in the oncogene GNAS are specific for diagnosing IPMNs, but suffer from low 
sensitivity (18). A variety of other cyst fluid biomarkers have also been explored (19–23); 
however, CEA remains the only widely applied molecular biomarker for differentiating 
mucinous from nonmucinous cysts. 
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 Proteases mediate a variety of critical processes in cancer, including invasion of the 
basement membrane via cleavage of extracellular matrix proteins and promotion of oncogenic 
signaling pathways through activation of growth factors and receptor tyrosine kinases (24,25). In 
pancreatic cancer, members of the cathepsin family of endolysosomal proteases are upregulated 
and found extracellularly. Aberrant secretion leads to cleavage of extracellular substrates, driving 
increased cellular invasion (26). Either genetic deletion or pharmacological inhibition of cysteine 
cathepsin activity decreases tumor progression and invasion (27,28).  
 Gene expression profiling studies of IPMNs and MCNs indicate overexpression of a 
range of proteases (29–31). Furthermore, analysis of protein expression in cyst fluid showed 
substantial differences in the abundance of pancreatic proteases and their cognate inhibitors 
between cyst types. The serine protease inhibitor SPINK1 was recently investigated as a 
biomarker for differentiating benign from malignant cysts (32,33). Collectively, these results 
suggest that there may be altered levels of proteolytic activity between mucinous and 
nonmucinous cysts and that these differences could be exploited to distinguish the type of lesion 
and its associated malignant potential. 
 In the current study, we applied a global protease profiling technology to discover 
proteolytic activity markers for differentiating mucinous from nonmucinous cysts. Using this 
approach, we identified enhanced aspartyl protease activity in mucinous cysts, due to 
upregulation of gastricsin and cathepsin E. We characterized the localization of both aspartyl 
proteases within the dysplastic tissue surrounding the mucinous cysts and determined that 
gastricsin expression was dependent on the degree of dysplasia. Lastly, highly selective 
fluorescent substrates for gastricsin and cathepsin E both confirmed their upregulated activities 
and outperformed CEA for differentiating mucinous from nonmucinous pancreatic cystic lesions. 
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3.4 Materials and methods 
Patients and sample acquisition 
Pancreatic cyst fluid samples were collected from preconsented patients under institutional 
review board approved protocols and in accordance with U. S. Common Rule at the University 
of California San Francisco, the University of Pittsburgh Medical Center, Indiana University 
School of Medicine, and Stanford University School of Medicine. Patient information is 
summarized in Table S1. All patients included in our study underwent surgical resection of their 
cystic lesion and have a pathologically confirmed diagnosis.  The highest grade of dysplasia 
observed during pathological evaluation of each cystic lesion is reported. Samples were collected 
either at the time of surgical resection or during diagnostic endoscopic ultrasound prior to 
resection of the cystic lesion. Cyst fluid samples were split into 100 µL aliquots and frozen to -80 
°C within 60 minutes of collection. Samples underwent at most two freeze-thaw cycles prior to 
experimental analysis. Total cyst fluid protein concentration was determined by the 
bicinchoninic acid assay. CEA levels were evaluated for the majority of samples, but were 
unavailable in 21 cases due to limited cyst fluid volume.  
 
Multiplex substrate profiling by mass spectrometry (MSP-MS) assay 
The MSP-MS assay was performed as previously described (34). Cyst fluid was diluted to 100 
µg/mL in assay buffer (either pH 7.5 phosphate buffer or pH 3.5 acetate buffer) and pre-
incubated for 10 minutes. For analysis of protease inhibitor sensitivity, 1 mM AEBSF (Sigma, 
A8456), 2 µM E-64 (Sigma, E3132), 2 µM pepstatin (Sigma, P5318), 2 mM 1,10-phenanthroline 
(Sigma, 131337), or DMSO were included in pre-incubation. The 228 tetradecapeptide library 
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was split into two pools and diluted in assay buffer to a concentration of 1 µM of each peptide. 
75 µL of diluted cyst fluid and peptide pools were then combined and incubated at room 
temperature. 30 µL aliquots were removed after 15 and 60 minutes, protease activity quenched 
with 8 M guanidinium hydrochloride, and flash-frozen in liquid N2. For recombinant gastricsin 
(R&D Systems, 6186-AS), cathepsin D (R&D Systems, 1014-AS), and cathepsin E (R&D 
Systems, 1294-AS), the MSP-MS assay was performed as described above with slight 
modifications: 10 nM of recombinant protease in pH 3.5 acetate buffer was used and aliquots 
were removed after 15, 60, and 240 minutes. 
 Prior to peptide cleavage site identification by mass spectrometry, samples were desalted 
using C18 tips (Rainin). Mass spectrometry analysis was carried out with an LTQ Orbitrap XL 
mass spectrometer coupled to a 10,000 psi nanoACQUITY Ultra Performance Liquid 
Chromatography (UPLC) System (Waters) for peptide separation by reverse phase liquid 
chromatography (RPLC). Peptides were separated over a C18 column (Thermo) and eluted by 
applying a flow rate of 300 nL/min with a 65-minute linear gradient from 2-30% acetonitrile. 
Survey scans were recorded over a 325-1500 m/z range and the six most intense precursor ions 
were fragmented by collision-induced dissociation (CID) for MS/MS.  
 Raw mass spectrometry data was processed to generate peak lists using MSConvert. Peak 
lists were then searched in Protein Prospector v. 5.10.0 (35) against a custom database containing 
the sequences from the 228 tetradecapeptide library. Searches used a mass accuracy tolerance of 
20 ppm for precursor ions and 0.8 Da for fragment ions. Variable modifications included N-
terminal pyroglutamate conversion from glutamine or glutamate and oxidation of tryptophan, 
proline, and tyrosine. Searches were subsequently processed using the MSP-xtractor software 
(http://www.craiklab.ucsf.edu/extractor.html), which extracts the peptide cleavage site and 
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spectral counts of the corresponding cleavage products. Spectral counts were used for the relative 
quantification of peptide cleavage products. 	
Proteomic analysis of cyst fluid samples 
Cyst fluid samples were processed for proteomic analysis using a standard protocol. Briefly, 8 µg 
of cyst fluid protein was denatured in 40 µL of 6 M urea. Disulfide bonds were reduced with 10 
mM dithiothreitol and free thiols were subsequently alkylated with 12.5 mM iodoacetamide. 
Samples were then diluted to with 25 mM ammonium bicarbonate to 2 M urea and digested with 
100 ng trypsin for 16 hours at 37 °C. Following trypsin digestion, samples were desalted with 
C18 tips (Rainin), dried, and resuspended in 0.1% formic acid. Triplicate LC-MS/MS analysis of 
all samples was performed as described above and details for this and protein identification are 
provided in the Supplemental Methods and Materials. 
 Label-free quantitation was used to compare relative abundance of the three aspartyl 
proteases identified in cyst fluid samples. The Skyline software package was used to obtain 
extracted ion chromatograms and peak areas for precursor ions from the aspartyl proteases (36). 
To correct for potential differences in protein loading between runs, peak areas were normalized 
by the median peak area of all fragmented ions from that run. The average peak area of the 
precursor ions from a given aspartyl protease was then used to estimate the abundance in each 
cyst fluid sample. 
 
Western blots of gastricsin and cathepsin E 
Cyst fluid protein (2 µg) or recombinant protease (20 ng) was pre-incubated for 30 minutes in 
either pH 7.5 phosphate buffer or pH 3.5 acetate buffer. Samples were then subjected to 
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electrophoresis on a 10% NuPAGE Bis-Tris gel. Proteins were transferred to polyvinylidene 
fluoride membranes and blocked in Tris-buffered saline with 0.1% Tween (TBS-T) and 5% 
(w/v) non-fat dry milk for 2 hours at room temperature. Membranes were then incubated with 
either rabbit anti-gastricsin antibody (1:500; Abcam, ab104595) or rabbit anti-cathepsin E 
antibody (1:1,000; Abcam, ab49800) for 1 hour at room temperature. Following a wash in TBS-
T, horseradish peroxidase (HRP)-conjugated secondary antibody (1:15,000; Abcam, ab97051) 
was applied for 2 hours at room temperatures. Proteins were detected with the enhanced 
chemiluminescence (ECL) detection system (Thermo). 
 
Animal strains 
The following mice strains were used: Ptf1a-Cre (gift of Christopher Wright, Vanderbilt 
University, Nashville, Tennessee, USA), LSL-KrasG12D (gift of Dave Tuveson, Cold Spring 
Harbor Laboratory, USA), Brg1f/f (gift of David Reisman, University of Florida, USA with 
permission of Pierre Chambon). Mice were crossed on a mixed background. The UCSF 
Institutional Care and Use of Animals Committee (IACUC) approved all mouse experiments. 	
Immunohistochemical analysis of pancreatic tissue 
Tissue samples were obtained from patients who underwent resection of pancreatic cystic lesions 
at UCSF. Gastricsin and cathepsin E immunohistochemistry assays were developed and 
performed on a Ventana Discovery Ultra automated slide stainer (Ventana Medical Systems).  In 
brief, formalin-fixed, paraffin-embedded (FFPE) samples (4 µm sections) were deparaffinized 
using EZPrep (Ventana Medical Systems) followed by treatment with antigen retrieval buffer 
(Ventana Medical Systems, 950-124). Specimens were incubated with either goat anti-gastricsin 
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antibody (1:300; Santa Cruz, sc-51185) or goat anti-cathepsin E antibody (1:200; Santa Cruz, sc-
6508) for 32 minutes at 36 °C. OmniMap anti-goat secondary antibody (Ventana Medical 
Systems, 760-4647) was then applied for 16 minutes before employing a DAB detection kit 
(Ventana Medical Systems, 760-500). All samples were counterstained with haematoxylin and 
Bluing Reagent (Ventana Medical Systems, 760-2037). H&E staining of tissue sections was 
performed using standard protocols. 
 Mouse pancreatic tissue samples were collected from 8 Ptf1a-Cre; LSL-KrasG12D; Brg1f/f 
animals between 3 and 40 weeks of age. FFPE samples (5 µm sections) were deparaffinized with 
xylene and subsequently rehydrated. Sections were either subjected to H&E staining or heat-
induced epitope retrieval with Citra buffer (BioGenex; HK086). Primary antibodies (goat anti-
mouse) for cathepsin E (1:1,000; R&D Systems; AF1130) and gastricsin (1:1,000; Santa Cruz; 
sc-51188) were incubated with sections overnight at 4 °C. Anti-goat secondary antibody (1:200; 
Vector Labs; BA-9500) was then added to sections for 1 hour at room temperature. ABC (Vector 
Labs; PK-6100) and DAB kits (Vector Labs; SK-4100) were employed for detection. Sections 
were counterstained with haematoxylin and incubated in 0.25% ammonium hydroxide for 
bluing.  
 
Peptide synthesis 
Synthesis of internally quenched fluorescent peptides was conducted using standard Fmoc solid-
phase peptide synthesis on a Syro II automated synthesizer (Biotage). Details are included in the 
Supplemental Methods and Materials. 	
Fluorescent protease activity assays 
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All fluorescent protease activity assays were performed in triplicate in black, round-bottom 384 
well plates. Assays were run for 1 hour in 15 µL of acetate buffer with 0.01% Tween. The pH of 
the acetate buffer was adjusted to promote activity of either aspartyl protease (pH 3.5 for the 
cathepsin E substrate and pH 2.0 for the gastricsin substrate). 10 µM of substrate was used for all 
assays (unless otherwise indicated) and was incubated with either 10 nM of recombinant 
protease or 50 µg/mL of cyst fluid protein. For kinetic analysis of gastricsin activity, the 
substrate concentration ranged from 0.1-25 µM. Fluorescent substrate cleavage was monitored 
with a Biotek Synergy HT plate reader using excitation and emission wavelengths of 328 nm and 
393 nm, respectively. Selectivity of the recombinant proteases was assessed by comparing the 
initial velocity of substrate hydrolysis in relative fluorescent units per second (RFU/sec). For cyst 
fluid samples, we compared the change in endpoint RFU relative to wells that contained 
substrate, but no cyst fluid.  	
Statistical analysis and data presentation 
A two-tailed Mann-Whitney U test was used to compare the differences in CEA abundance, 
gastricsin activity, and cathepsin E activity between mucinous and nonmucinous cysts. 
Univariate and multivariate logistic regression models were used for cyst prediction. Receiver 
operating characteristic (ROC) curves and Youden’s J statistic were employed to identify the 
optimal cutoff. All mass spectrometry data (spectral counts and peak areas) was log2 
transformed and analyzed with unpaired two-tailed t-tests. GraphPad Prism was used to fit 
kinetic data and generate scatter plots and bar charts. Volcano plots, heat maps, venn diagrams, 
ROC curves, and logistic regression models were generated in RStudio v. 0.98.1091. iceLogo 
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software was used to visualize patterns in peptide cleavage sites at ±4 positions away from the 
scissile bond (37). 
 
Supplemental Methods and Materials 
Peptide synthesis 
Peptide synthesis reactors were charged with Wang resin preloaded with Fmoc-
Lys(dinitrophenol) (Anaspec, A23856).  Coupling reactions were conducted on a 0.0125 mmol 
scale in 500 µL of DMF with 5 equivalents of Fmoc amino acid (Anaspec), 4.9 equivalents of 
HCTU (Anaspec), and 20 equivalents of N-methylmorpholine (NMM). Reactions were run for 8 
minutes while shaking at ambient temperature and atmosphere. Fmoc deprotection was 
conducted by incubation with 500 µL 40% 4-methlypiperidine in DMF for 3 minutes, followed 
by 500 µL 20% 4-methlypiperidine in DMF for 10 minutes. Substrates were capped with a C-
terminal Lys-(7-methoxycoumarin-4-acetic acid)-OH (EMD Millipore, 852095) followed by two 
D-Arg residues to enhance solubility. Peptides were removed from resin by incubating with 500 
µL of cleavage solution (95% trifluoroacetic acid, 2.5% water, 2.5% Triisopropylsilane) and 
shaking for 1h.  Crudes were precipitated in 10 mL cold diethyl ether and isolated by 
centrifugation.  Peptides were purified by HPLC and the correct mass was confirmed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry. 
 
LC-MS/MS analysis of cyst fluid samples and protein identification 
Triplicate LC-MS/MS analysis of all samples was performed on an LTQ Orbitrap XL mass 
spectrometer and UPLC system described previously. Peptides were separated by RPLC over a 
C18 column (Thermo). A 60-minute linear gradient from 2-15% acetonitrile with a flow rate of 
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300 nL/min was used for elution of peptides. Survey scans were recorded over a 325-1500 m/z 
range.  The six most intense precursor ions from each survey scan were fragmented by collision-
induced dissociation (CID) for MS/MS analysis. 
 Peak lists were generated using an in-house software called PAVA and searched in 
Protein Prospector v. 5.10.0 (35). Peak lists were searched against all human protein sequences 
in the SwissProt database (downloaded December 1, 2015 with 549,832 sequence entries). This 
database was concatenated with a fully randomized set of entries to estimate the false discovery 
rate (FDR). For database searches, peptides sequences were matched to tryptic peptides with up 
to two missed cleavages. Carbamidomethylation of cysteine residues was used as a constant 
modification and variable modifications included oxidation of methionine, N-terminal 
pyroglutamate from glutamine, N-terminal acetylation, and loss of N-terminal methionine. The 
mass accuracy tolerance was set to 20 ppm for precursor ions and 0.8 Da for fragment ions. 
Protein Prospector score thresholds of 22 for the protein score and 15 for the peptide score were 
used and yielded a FDR of less than 1%. All reported proteins were identified by at least 2 
unique peptides. 
 
3.5 Results 
Global protease activity profiling of patient cyst fluid 
To identify differences in proteolytic activity between mucinous and nonmucinous cysts we used 
our MSP-MS assay, which is a global and unbiased substrate-based protease profiling approach 
(34). In the MSP-MS assay, a physicochemically diverse library of 228 tetradecapeptide 
substrates is incubated with a protease-containing sample of interest and tandem mass 
spectrometry is used to monitor protease-derived peptide cleavage products. We have previously 
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validated this assay through analysis of all classes of protease and used it to develop selective 
substrate probes (38–40). 
 Using the MSP-MS assay, we profiled 16 mucinous and 7 nonmucinous cyst fluid 
samples. To capture a broad range of protease activities, we performed the assay under acidic 
conditions and at neutral pH. At pH 7.5, we detected a total of 1117 unique peptide cleavages 
among the patient sample set (Fig. 1A). Only 7 peptide cleavages met our selectivity criteria for 
differentiating mucinous from nonmucinous cysts (+/- 1 log2(mucinous/nonmucinous), p < 0.05). 
6 of these cleavages were enriched in nonmucinous cysts, and overall, there was a slight trend 
toward increased proteolytic activity in fluid from nonmucinous cysts (Fig. S1A). When the 
same samples were assayed at pH 3.5, a total of 691 peptide cleavages were detected, and we 
observed increased proteolytic activity in the mucinous cysts (Fig. 1B and Fig. S1B). All 35 
unique substrate cleavages that differentiated mucinous from nonmucinous cysts were enriched 
in the mucinous set. The degree of dysplasia within a mucinous cyst is also an important factor in 
determining whether surgical intervention is recommended. However, no major differences in 
protease activity were evident between mucinous cysts with low- or high-grade dysplasia (Fig. 
S2). 
 We generated an iceLogo frequency plot to visualize the substrate specificity pattern of 
the 35 mucinous-specific peptide cleavages detected at pH 3.5 (Fig. 1C) (37). At the P1 and P1ʹ 
positions, which flank the cleavage site, there was a predominant enrichment of hydrophobic 
amino acids with the aromatic residues tyrosine and tryptophan more favored at P1. This mirrors 
the previously reported substrate specificity of lysosomal aspartyl proteases (41,42).  	
Identification of cathepsin E and gastricsin in mucinous cysts 
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We next sought to identify the specific proteases within the mucinous cysts that are responsible 
for the increased acid-optimal cleavage of the 35 mucinous-specific substrates. To aid in the 
characterization of protease activity, we initially focused on a single mucinous cyst fluid sample 
that cleaved 30 out of the 35 substrates. 
 We treated the cyst fluid with broad-spectrum inhibitors against all major protease classes 
and analyzed changes in cleavage of the 35 mucinous-specific substrates by MSP-MS (Fig. 2A). 
Treatment with the aspartyl protease inhibitor pepstatin fully inhibited cleavage of 20 mucinous-
specific substrates and partially inhibited cleavage of 8 additional substrates. The other broad-
spectrum protease inhibitors minimally affected cleavage of the mucinous-specific substrates. 
The serine protease inhibitor AEBSF and the metal chelator 1,10-phenanthroline only inhibited 
cleavage of 3 substrates each. In a second mucinous cyst fluid sample, we confirmed that 
aspartyl protease inhibition with pepstatin blocks cleavage of the majority of the mucinous-
specific substrates (Fig. S3). 
 Our inhibition data demonstrated that aspartyl proteases have increased activity in 
mucinous cysts. Therefore, we performed shotgun proteomic analysis of a set of mucinous (n=4) 
and nonmucinous cysts (n=3) to determine if there were differences in the abundance of 
individual aspartyl proteases. This analysis identified three aspartyl proteases – cathepsin D, 
cathepsin E, and gastricsin (Table S2). Label-free quantitation using precursor ion abundance, 
revealed that cathepsin D was present at similar levels in the mucinous and nonmucinous cysts, 
whereas cathepsin E and gastricsin were significantly more abundant in the mucinous cysts (Fig. 
2B and Table S3). Aspartyl proteases are synthesized as inactive zymogens that undergo 
enzymatic maturation at an acidic pH (43). As the tumor microenvironment is known to be 
acidic, we investigated whether cathepsin E and gastricsin were present in the pro- or mature 
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forms. Exposure of fluid from a mucinous cyst to acidic pH induced a mass shift in cathepsin E 
and gastricsin that was comparable to that observed using recombinantly produced proteins (Fig. 
2C), indicating that both proteases are released into cyst fluid in their proforms. As expected, no 
cathepsin E or gastricsin was detected in fluid from a representative nonmucinous cyst. 
Collectively, these results demonstrate that the proforms of cathepsin E and gastricsin are 
differentially expressed in mucinous cysts and that this induction is responsible for the increased 
proteolytic activity under acidic conditions. 	
Immunohistochemical analysis of gastricsin and cathepsin E in mucinous cysts 
We further examined overexpression of cathepsin E and gastricsin in 14 mucinous cysts using 
immunohistochemical (IHC) analysis. Cytoplasmic gastricsin staining was observed in the 
epithelial cells lining 11 of the 14 mucinous cysts examined (Table S4). Interestingly, gastricsin 
expression was primarily associated with regions of low-grade dysplasia, and no staining was 
observed in regions of high-grade dysplasia (Figs. 3A-D). Gastricsin staining was also apparent 
in areas of low-grade dysplasia within mucinous cysts that contained both low- and high-grade 
dysplasia. Cytoplasmic cathepsin E was detected in all 14 mucinous cysts examined; however, 
staining did not show a dependence on the degree of dysplasia (Figs. 3E-H). No gastricsin or 
cathepsin E staining was evident in the neighboring normal ductal epithelium or stromal tissue. 
In addition, neither protease was detected in either of the two nonmucinous SCAs examined.  
We also examined expression of gastricsin and cathepsin E in an IPMN genetic mouse 
model. Ptf1a-Cre; LSL-KrasG12D; Brg1f/f mice develop cystic lesions of the pancreas that closely 
resemble human IPMNs (44). Consistent with the above results, we observed cytoplasmic 
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gastricsin and cathepsin E staining in the epithelial cells surrounding the cystic lesion (Fig. S4). 
Once again, there was no staining in normal pancreatic tissue.  	
Development of a gastricsin selective fluorescent substrate 
The MSP-MS assay is ideal for discovering global differences in protease activity, but is not 
readily amenable for use as a diagnostic tool. Therefore, we sought to identify sensitive and 
selective fluorescent substrates that could be used in a standard microplate format to distinguish 
mucinous from nonmucinous cysts.  
 We focused on designing a gastricsin selective substrate as a cathepsin E selective 
substrate has been previously reported (45). We first analyzed the substrate specificity of 
recombinant cathepsin E and gastricsin using the MSP-MS assay (Fig. 4A). We also profiled 
recombinant cathepsin D, as it was detected in cyst fluid samples by our shotgun proteomic 
analysis (Fig. 2B), and therefore, we wanted to ensure that the synthesized substrates are not 
cleaved by this protease. Cathepsins E and D showed highly similar substrate specificity with a 
Pearson correlation coefficient of 0.81 and both proteases displayed a clear preference for 
hydrophobic residues in the P1 and P1ʹ positions. Gastricsin also preferred hydrophobic residues 
in the P1 and P1ʹ positions, however, direct comparison of the amino acid enrichment profiles 
revealed that gastricsin also has distinct cleavage preferences (Fig. 4B). Most notably, gastricsin 
shows a significantly stronger preference for tyrosine and tryptophan in the P1 position. 
Gastricsin also slightly favored small amino acids, such as glycine, serine, and alanine, in the P1’ 
position.  
 Using the MSP- MS assay, we identified 75 peptides that were cleaved by gastricsin and 
not by cathepsins D or E (Fig. 4C). We used the specificity information from Fig. 4A-B to select 
	 84	
a single peptide substrate that we expected to be highly selective for gastricsin. In particular, we 
chose a peptide that was cleaved by gastricsin with a tryptophan and alanine in the P1 and P1ʹ 
positions, respectively. We synthesized an internally quenched, fluorescent substrate 
incorporating the P4 to P4ʹ amino acids from this peptide. This substrate was found to be greater 
than 120-fold selective for gastricsin over both cathepsins D and E (Fig. 4D) and is cleaved with 
a kcat/Km of 4.8 × 105 M-1/s-1 (Fig. S5). We also synthesized the previously reported cathepsin E 
selective substrate and confirmed that it is more than 100-fold selective for cathepsin E over both 
cathepsin D and gastricsin (Fig. 4D) (45). Lastly, we confirmed that we could use these 
substrates to monitor cathepsin E and gastricsin protease activity in cyst fluid. Indeed, both 
substrates were cleaved in fluid from a mucinous cyst and this activity was fully inhibited by pre-
incubation with pepstatin (Fig. S6). 	
Gastricsin and cathepsin E activity differentiate mucinous from nonmucinous cysts 
We next used the gastricsin and cathepsin E fluorescent substrates to assess their relative 
protease activities in cyst fluid samples to determine if these activities could be used to 
differentiate mucinous from nonmucinous cysts. We first analyzed the 23 cyst fluid samples that 
we previously profiled using the MSP-MS assay. Cleavage of both the gastricsin and cathepsin E 
substrate was significantly higher in mucinous relative to nonmucinous cysts (Fig. S7). This 
prompted us to assess cathepsin E and gastricsin activity in a validation cohort comprised of an 
additional 87 cyst fluid samples. Again, mucinous cysts displayed significantly increased levels 
of gastricsin and cathepsin E activity (Fig. S7). There were no significant differences in activity 
between the two patient cohorts. Analysis of all 110 patient samples revealed that gastricsin 
activity was on average increased more than 6-fold in mucinous cysts, while cathepsin E activity 
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was increased only 2-fold (Fig. 5A-B). The ROC curve for gastricsin activity exhibited an area 
under the curve (AUC) of 0.979 for distinguishing mucinous cysts (Fig. 5C and Table S5). At the 
optimal cutoff of a 1.23-fold change in fluorescence, gastricsin activity demonstrated a 
specificity of 100% and a sensitivity of 93%. Cathepsin E activity had an AUC of 0.828 and, 
using this same optimal cutoff, displayed 92% specificity and 70% sensitivity for differentiating 
mucinous from nonmucinous cysts. Gastricsin and cathepsin E activity did not show a 
dependence on the type of mucinous cyst or the degree of dysplasia within a mucinous cyst (Fig. 
S8). Considering that gastricsin expression was only observed in regions of low-grade dysplasia 
(Fig. 3), we were surprised to observe that gastricsin activity was also not associated with the 
degree of dysplasia. This is likely because highly dysplastic and invasive mucinous lesions also 
often contain regions of low-grade dysplasia. We also examined whether gastricsin or cathepsin 
E activity were correlated with features from the revised Sendai criteria, which is a widely 
applied consensus guidelines for the management of mucinous cysts (8). Neither gastricsin nor 
cathepsin E activity showed significant differences in relation to the Sendai features we assessed 
(Table S6). 
 CEA levels were independently measured for 89 of the cyst fluid samples, and we 
compared abundance between mucinous (n=55) and nonmucinous cysts (n=34). As expected, 
CEA was significantly elevated in the mucinous cysts (Fig. S9). The CEA ROC curve exhibited 
an AUC of 0.865 for distinguishing mucinous cysts from nonmucinous cysts (Fig. 5C). CEA-
based classification underperformed gastricsin activity, but was comparable to cathepsin E 
activity-based classification. For CEA, a cutoff level of 192 ng/mL is the commonly used clinical 
standard for differentiating mucinous from nonmucinous cysts (46). At this cutoff, CEA 
demonstrated a specificity of 94% and a sensitivity of 65%, which is consistent with what has 
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been previously reported. All 19 of the mucinous cyst fluid samples with CEA levels below the 
standard cutoff of 192 ng/mL were correctly classified by gastricsin activity. Additionally, the 
two nonmucinous cysts with CEA levels above 192 ng/mL were also correctly classified by 
gastricsin activity.  
We also assessed whether combined analysis of CEA with gastricsin and cathepsin E 
activity could better differentiate mucinous from nonmucinous cysts. Gastricsin activity with 
CEA evaluation resulted in a classifier with an AUC of 0.998 (Fig. 5C), exhibiting a specificity 
of 100% and sensitivity of 98%. Inclusion of all three markers did not lead to improved 
differentiation of mucinous from nonmucinous cysts (Table S5). 
 
3.6 Discussion 
Although pancreatic cysts are being detected at an increasing rate, available diagnostic tests do 
not accurately discriminate between cyst types. Mucinous cysts have malignant potential and 
may require resection, while nonmucinous cysts are considered benign and require no further 
evaluation if these lesions are asymptomatic. Increasing the level of certainty in this distinction 
would spare some patients unnecessary surgical resections and reduce the need for ongoing 
surveillance for many more individuals. In this study, we used an unbiased and global substrate-
based profiling strategy coupled with proteomics, to identify distinguishing protease activities in 
cyst fluid samples. Using this approach, gastricsin and cathepsin E activities were found to be 
promising markers for differentiating benign nonmucinous cysts from potentially malignant 
mucinous cysts. Selective fluorescent substrates both confirmed induction of these proteases in 
mucinous cysts and enabled sensitive and specific differentiation of these lesions in 110 patient 
samples.   
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 To date, CEA remains the most widely used clinical biomarker for differentiating 
mucinous from nonmucinous cysts. However, the performance of this marker is generally 
considered suboptimal. Indeed, CEA analysis was only 76% accurate in our study at the standard 
cutoff of 192 ng/mL. Gastricsin activity was 95% accurate, and correctly classified all 21 cysts 
that were misclassified by CEA, clearly demonstrating the clinical utility of this marker. 
Furthermore, we were able to improve classification accuracy to 99% by combining CEA with 
gastricsin activity analysis. 
 Preoperatively determining the degree of dysplasia within a mucinous cyst is another 
major challenge for ensuring appropriate clinical intervention. However, the protease activity 
markers identified in this study do not differentiate between mucinous cysts with low- or high-
grade dysplasia. Although this is a limitation of our markers, correctly differentiating mucinous 
from nonmucinous cysts is a critical first step in deciding which cysts should undergo resection. 
For example, pancreatic resection of the 39 benign nonmucinous cysts included in this study 
could potentially have been avoided through the application of our assay. In addition, 19 
mucinous cysts within our patient cohort had CEA levels below the standard cutoff of 192 
ng/mL. In our high-volume pancreatic centers, radiographic and clinical features allowed 
experienced clinicians to correctly identify these cysts as mucinous. However, medical centers 
without dedicated cyst specialists may be inclined to misclassify these samples as nonmucinous 
and would greatly benefit from our simple and accurate diagnostic assay. A number of molecular 
and clinical markers have recently shown promise for distinguishing mucinous cysts based on 
their degree of dysplasia (19,23). A sequential diagnostic strategy may emerge in which 
gastricsin and cathepsin E activity are used to determine if a lesion is mucinous, followed by 
analysis of a secondary marker to define the degree of dysplasia. Assessing gastricsin and 
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cathepsin E activity in combination with other promising markers will be a primary focus of 
future work.  
 Previous gene expression profiling studies of IPMNs and MCNs demonstrated 
overexpression of gastricsin and cathepsin E mRNA (29–31). However, the protein levels and 
activity of these aspartyl proteases has not been previously investigated within these lesions. 
Protease activity is particularly well suited to the development of a rapid and simple diagnostic 
test for differentiating cysts. Activity-based detection is highly sensitive because of catalytic 
signal amplification. Indeed, the assays described in this study use less than 5 µL of cyst fluid, 
whereas CEA tests often require at least 500 µL. Furthermore, unlike immunoassays, protease 
activity assays do not require the costly development of high-quality antibody reagents. 
Spectrophotometric assays can be readily adapted to the standard plate readers present in clinical 
laboratories, and there are already several examples of such protease activity assays in common 
clinical use for other indications (47,48). 
 We were particularly interested to observe that gastricsin expression within mucinous 
cysts was primarily associated with areas of low-grade dysplasia and was absent in high-grade 
dysplasia, although we were only able to assess four cysts containing regions of high-grade 
dysplasia. Previous work demonstrated that gastricsin and other foregut markers are 
overexpressed in other pancreatic cancer precursor lesions, reflecting a cellular dedifferentiation 
step prior to malignant transformation (49). Gastricsin overexpression within IPMNs and MCNs 
might be reflective of a similar process. In support of this hypothesis, recent work using the same 
IPMN genetic mouse model examined in this study showed that cellular dedifferentiation is a 
critical step in the development of IPMNs (44,50). Dedifferentiation within this genetic mouse 
model is transient and occurs prior to the development of invasive cancer, which may explain 
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why gastricsin expression is associated with regions of low-grade dysplasia. In contrast to 
gastricsin, we did not observe an association between cathepsin E expression and the degree of 
dysplasia present within a mucinous cyst. This suggests that different processes control the 
expression of these two proteases and that cathepsin E levels are less reflective of cellular 
identity. Additional studies using the recently developed genetic mouse models of mucinous 
cysts are needed to characterize how the expression of these proteases is regulated and what roles 
– if any – gastricsin and cathepsin E are playing in neoplastic transformation (44).  
 In summary, our results demonstrate that gastricsin and cathepsin E activity are sensitive 
and specific markers for differentiating mucinous from nonmucinous pancreatic cystic lesions. In 
particular, gastricsin activity is a promising candidate for the development of a simple, 
diagnostic test with superior performance to CEA. This could provide clinical stratification to 
properly manage the growing problem of pancreatic cysts. 
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3.8 Figures 
 
Figure 3.1 Comparison of global proteolytic activity in mucinous and nonmucinous cysts by 
MSP-MS. Volcano plots displaying the peptide cleavages generated by mucinous (n=16) and 
nonmucinous cysts (n=7) when assayed at pH 7.5 (A) or pH 3.5 (B). Spectral counts of peptide 
cleavage products were used for relative quantification of the fold change 
(mucinous/nonmucinous) and hypothesis testing. Cleavages that met the criteria for 
differentiating mucinous from nonmucinous cysts (+/- 1 log2(fold change), p < 0.05) are shown 
in blue. The substrate specificity of the cleavages within the red box is displayed with an 
iceLogo plot (C). Residues shown are statistically significant with p < 0.05.   
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Figure 3.2 Identification of enriched aspartyl protease activity in mucinous cysts. (A) 
Heatmap displaying cleavage of 30 mucinous-specific substrates following treatment of a 
mucinous cyst fluid sample with DMSO or various broad-spectrum protease inhibitors. Spectral 
counts were used for relative quantification of peptide cleavage products. Vertical bar (|) 
indicates the site of cleavage within substrates. (B) Label-free quantitation of aspartyl protease 
relative abundance in mucinous (M) and nonmucinous (NM) cysts. (C) Western blot analysis of 
recombinant (r) and cyst fluid-derived cathepsin E and gastricsin. Samples were pre-incubated at 
the indicated pH for 10 minutes. 
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Figure 3.3 Immunohistochemical analysis of gastricsin and cathepsin E in mucinous cysts. 
Histological analysis of mucinous cysts with low-grade dysplasia (A, B, E, F) and high-grade 
dysplasia (C, D, G, H). Gastricsin (A, C), cathepsin E (E, G), and haematoxylin and eosin 
(H&E) staining (B, D, F, H) in IPMNs (A-F) and MCNs (G, H). Scale bar is 10 µm. 
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Figure 3.4 Design and synthesis of gastricsin selective fluorescent substrate. (A) Substrate 
specificity of cathepsin D, cathepsin E, and gastricsin as determined by MSP-MS. Residues 
shown in iceLogo are statistically significant with p < 0.05. (B) Heatmap comparing the amino 
acid enrichment Z-scores for gastricsin relative to cathepsin D and cathepsin E. (C) Venn 
diagram depicting the unique and overlapping cleavages detected by MSP-MS with cathepsin D, 
cathepsin E, and gastricsin. (D) Cleavage of the fluorescent substrates by cathepsin D, cathepsin 
E, and gastricsin. Activity was normalized to 1.00 based on the maximal activity against each 
substrate. Red arrow indicates the site of cleavage. Error bars denote standard error of the mean 
(SEM) from triplicate analysis.  
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Fig. 3.5 Quantification of gastricsin and cathepsin E activity in 110 cyst fluid samples. 
Analysis of gastricsin (A) and cathepsin E (B) activity in nonmucinous (NM) and mucinous (M) 
cysts using fluorescent substrates. (C) ROC curves comparing sensitivity and specificity of CEA, 
gastricsin, cathepsin E, and CEA and gastricsin in combination. 
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Supplementary Figure 3.1 Comparison of global proteolytic activity in mucinous and nonmucinous cysts by 
MSP-MS. Histograms depicting the number of cleavages enriched in mucinous and nonmucinous cysts at pH 3.5 
(B) and pH 7.5 (B). Spectral counts of peptide cleavage products were used for quantification of the fold change 
(mucinous/nonmucinous) and counts are the number of peptide cleavages in each bin. 
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Supplementary Figure 3.2 Comparison of global proteolytic activity in mucinous cysts with low- and high-
grade dysplasia. Volcano plots displaying the peptide cleavages generated by the mucinous cysts with low-grade 
dysplasia (n=9) and high-grade dysplasia (n=7) at pH 3.5 (A) and pH 7.5 (B). Fold change corresponds to low-grade 
dysplasia/high-grade dysplasia.  
	 104	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3.3 Analysis of pepstatin inhibition on protease activity through MSP-MS. Heatmap 
displaying cleavage of 28 mucinous-specific substrates following treatment of a mucinous cyst fluid sample with 
DMSO or pepstatin. Spectral counts were used for relative quantification of peptide cleavage products. Vertical bar 
(|) indicates the site of cleavage within substrates. 
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Supplementary Figure 3.4 Immunohistochemical analysis of IPMN genetic mouse model. 
Immunohistochemical analysis of gastricsin (A) and cathepsin E (B) in a cystic lesion from a 40-week-old Ptf1a-
Cre; LSL-KrasG12D; Brg1f/f  mouse. 
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Supplementary Figure 3.5 Kinetic analysis of gastricsin selective substrate. Michaelis-Menten analysis of 
cleavage of DEGW | ALQH substrate by gastricsin. kcat/Km = X, Vmax is Y. Error bars denote SEM from triplicate 
analysis. 
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Supplementary Figure 3.6 Cleavage of aspartyl protease substrates in mucinous cysts. Pepstatin inhibition of 
cleavage of fluorescent substrates by a mucinous cyst fluid sample. Activity was normalized relative to DMSO 
control treatment and error bars denote SEM from triplicate analysis. 
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Supplementary Figure 3.7 Quantification of aspartyl protease activity in cyst fluid samples using fluorescent 
peptide substrates. Gastricsin (A) and cathepsin E (B) activity in samples analyzed by MSP-MS and fluorescence 
(n=23) and in samples from validation (V) cohort (n=87) that were just assayed using fluorescent substrates.  
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 Supplementary Figure 3.8 Analysis of gastricsin and cathepsin E activity in 71 mucinous cyst fluid samples. 
Gastricsin and cathepsin E activity in mucinous cysts with low- and high-grade dysplasia (A, B) or IPMNs and 
MCNs (C, D). 
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 Supplementary Figure 3.9 CEA levels in mucinous and nonmucinous cysts. Dashed line indicates the standard 
clinical cutoff of 192 ng/mL. 
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Tables 
Supplementary Table 3.1 Characteristics of 110 patients analyzed in this study. 
Internal ID Diagnosis Highest grade 
of dysplasia
Cyst size 
(mm)
Collection method 
(EUS/Surgery)
Age Gender Institution
14 IPMN High 22 Surgery 60 Female UCSF
15 IPMN High 19 Surgery 69 Male UCSF
23 IPMN Low 8 Surgery 55 Female UCSF
34 IPMN High 59 Surgery 78 Male UCSF
55 IPMN High 26 Surgery 69 Female Stanford
138 IPMN Low 65 EUS 68 Male Stanford
770 IPMN High 39 Surgery 72 Female Stanford
775 IPMN High 120 Surgery 78 Male Stanford
788 IPMN High 18 Surgery 64 Male Stanford
797 IPMN High 30 Surgery 79 Female Stanford
801 IPMN High 25 Surgery 68 Male Stanford
41 IPMN Low 18 Surgery 41 Male Pittsburgh
47 IPMN Moderate 31 Surgery 47 Female Pittsburgh
51 IPMN High 20 Surgery 51 Male Pittsburgh
52 IPMN Moderate 47 Surgery 52 Female Pittsburgh
53 IPMN Low 25 Surgery 53 Female Pittsburgh
54 IPMN Moderate 38 Surgery 54 Female Pittsburgh
62 IPMN Moderate 40 Surgery 62 Female Pittsburgh
64 IPMN Moderate 47 Surgery 64 Male Pittsburgh
69 IPMN Moderate 30 Surgery 69 Female Pittsburgh
77 IPMN Moderate 65 Surgery 77 Female Pittsburgh
85 IPMN High 27 Surgery 85 Female Pittsburgh
90 IPMN High NA EUS 69 Female Indiana
169 IPMN High 35 ERCP 75 Male Indiana
1177 IPMN High 57 Surgery 67 Female Indiana
1183 IPMN High 120 Surgery 78 Male Indiana
1187 IPMN High NA Surgery 66 Female Indiana
1209 IPMN High 50 Surgery 74 Male Indiana
1217 IPMN High 23 Surgery 58 Male Indiana
1233 IPMN High NA Surgery 71 Female Indiana
1250 IPMN Low 23 Surgery 68 Female Indiana
1251 IPMN Low 25 Surgery 79 Male Indiana
1252 IPMN High 11 Surgery 72 Male Indiana
1253 IPMN High 30 Surgery 63 Female Indiana
1255 IPMN Low 37 Surgery 80 Female Indiana
1272 IPMN Low 20 Surgery 40 Female Indiana
1275 IPMN High 20 Surgery 62 Male Indiana
157 IPMN Low 35 Surgery 84 Male Stanford
685 IPMN Low 4 Surgery 71 Female Stanford
733 IPMN Low 45 EUS 78 Male Stanford
755 IPMN Moderate 60 Surgery 60 Male Stanford
760 IPMN Moderate 35 Surgery 84 Female Stanford
761 IPMN Moderate 30 Surgery 74 Female Stanford
785 IPMN Low 90 Surgery 72 Male Stanford
786 IPMN Moderate 50 Surgery 71 Female Stanford
4 MCN Moderate 23 Surgery 57 Female UCSF
6 MCN High 22 Surgery 74 Female UCSF
125 MCN High 57 Surgery 54 Female UCSF
130 MCN High 125 Surgery 47 Female UCSF
30 MCN Moderate 60 Surgery 48 Male Stanford
136 MCN Low 100 Surgery 44 Female Stanford
139 MCN Low 140 Surgery 22 Female Stanford
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Supplementary Table 3.1 (continued) 
Internal ID Diagnosis
Highest 
grade of 
dysplasia
Cyst size 
(mm)
Collection 
method 
(EUS/Surg
ery)
Age Gender Institution
686 MCN Low 125 Surgery 44 Female Stanford
716 MCN Low 30 Surgery 65 Female Stanford
720 MCN Low 45 Surgery 49 Female Stanford
752 MCN High 152 Surgery 42 Female Stanford
768 MCN Low 65 Surgery 25 Female Stanford
787 MCN Low 30 Surgery 76 Female Stanford
799 MCN Moderate 70 Surgery 31 Female Stanford
42 MCN Moderate 100 Surgery 42 Female Pittsburgh
50 MCN High 215 Surgery 50 Female Pittsburgh
59 MCN Moderate 19 Surgery 59 Female Pittsburgh
74 MCN Low 115 Surgery 74 Female Pittsburgh
75 MCN Low 30 Surgery 75 Female Pittsburgh
1152 MCN Low 18 Surgery 61 Female Indiana
1182 MCN Low 50 Surgery 25 Female Indiana
1191 MCN Low 25 Surgery 24 Female Indiana
1261 MCN Low 40 Surgery 24 Female Indiana
1263 MCN High 28 Surgery 44 Male Indiana
1265 MCN Low 30 Surgery 50 Female Indiana
1269 MCN Low 50 Surgery 57 Female Indiana
81 Pseudocyst NA 55 EUS 48 Male Stanford
98 Pseudocyst NA 219 Surgery 30 Female Stanford
101 Pseudocyst NA 40 EUS 62 Female Stanford
126 Pseudocyst NA 90 EUS 57 Male Stanford
151 Pseudocyst NA 12 Surgery 55 Female Stanford
678 Pseudocyst NA 100 Surgery 56 Female Stanford
705 Pseudocyst NA 90 Surgery 60 Male Stanford
43 Pseudocyst NA 79 EUS 43 Male Pittsburgh
49 Pseudocyst NA 98 EUS 49 Male UCSF
63 Pseudocyst NA 91 EUS 63 Male Pittsburgh
70 Pseudocyst NA 100 Surgery 70 Male Pittsburgh
78 Pseudocyst NA 31 EUS 78 Female Pittsburgh
11 Pseudocyst NA NA EUS 68 Female Indiana
50 Pseudocyst NA NA Surgery 59 Female Indiana
159 Pseudocyst NA NA EUS 67 Male Indiana
311 Pseudocyst NA NA EUS 60 Male Indiana
1142 Pseudocyst NA NA Surgery 52 Male Indiana
1178 Pseudocyst NA NA Surgery 66 Female Indiana
1180 Pseudocyst NA NA Surgery 42 Female Indiana
1191 Pseudocyst NA NA Surgery 24 Female Indiana
1230 Pseudocyst NA NA Surgery 58 Female Indiana
21 SCA NA 20 Surgery 58 Male UCSF
87 SCA NA 160 Surgery 62 Male UCSF
68 SCA NA 50 EUS 59 Male Stanford
147 SCA NA 38 EUS 45 Female Stanford
679 SCA NA 65 Surgery 70 Female Stanford
732 SCA NA 100 Surgery 43 Female Stanford
748 SCA NA 60 Surgery 66 Male Stanford
767 SCA NA 105 Surgery 47 Male Stanford
802 SCA NA 60 Surgery 75 Female Stanford
10 SCA NA 40 Surgery 55 Male Indiana
121 SCA NA 110 EUS 33 Female Indiana
128 SCA NA 25 EUS 55 Female Indiana
409 SCA NA 45 Surgery 26 Female Indiana
852 SCA NA 25 Surgery 30 Female Indiana
1053 SCA NA 12 Surgery 41 Female Indiana
1218 SCA NA 82 Surgery 76 Female Indiana
1234 SCA NA 93 Surgery 76 Male Indiana
1283 SCA NA 30 Surgery 74 Female Indiana
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Supplementary Table 3.4 Cathepsin E and gastricsin staining in cyst tissue. 
 
 
Protein IPMN (HGD) IPMN (LGD) MCN (HGD) MCN (LGD) SCA
Gastricsin 0/3 4/4 0/1 4/6 0/2
Cathepsin E 3/3 4/4 1/1 6/6 0/2
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Supplementary Table 3.5 Diagnostic performance of individial and combination markers in 
cyst fluid samples. 
Markers AUC (95% CI)
Sensitivity (%)
(95% CI)
Sensitivity (%)
(95% CI)
Gastricsin + Cathepsin E + CEA 0.998 (0.995 - 1) 98.2 (90.3-100) 100 (89.7-100)
Gastricsin + CEA 0.998 (0.995 - 1) 98.2 (90.3-100) 100 (89.7-100)
Gastricsin + Cathepsin E 0.987 (0.971 - 1) 94.4 (0.9713 - 1) 100 (91.0-100)
Cathepsin E + CEA 0.909 (0.845 - 0.973) 83.6 (71.2-92.2) 94.1 (80.3-99.3)
Gastricsin 0.979 (0.952 - 1) 93.0 (84.3-97.7) 100 (91.0-100)
Cathepsin E 0.828 (0.75 - 0.907) 70.4 (58.4-80.7) 92.3 (79.1-98.4)
CEA 0.865 (0.792 - 0.938) 74.5 (61.5-85.3) 91.2 (76.3-98.14)
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Supplementary Table 3.6 Protease activity data in relation to revised Sendai criteria for 71 
mucinous cysts. 
 
Mucinous cyst features Fraction of 
mucinous cysts
Gastricsin activity: 
fluorescence fold change
Cathepsin E activity:
fluorescence fold change
All mucinous cysts 71/71 6.56 (5.11) 2.31 (2.00)
Worrisome features 56/71 6.43 (4.86) 2.34 (2.14)
      Cyst >3 cm 50/71 6.77 (4.90) 2.47 (2.23)
      Enhanced cyst wall 8/48 8.78 (6.12) 2.01 (0.82)
      Main duct 5-9 mm 10/70 8.74 (6.19) 2.35 (1.44)
      Nonenhancing mural nodule 1/46 2.03 14.3
      Abrupt change in caliber 4/71 6.20 (4.13) 2.40 (1.28)
High risk stigmata 26/71 5.73 (4.66) 2.55 (2.70)
      Jaundice 7/69 7.75 (5.57) 3.21 (1.67)
      Enhancing mural nodule 15/71 3.90 (3.61) 2.64 (3.34)
      Main duct >10 mm 13/70 5.03 (4.35) 1.81 (1.10)
No worrisome features or 
high risk stigmata
7/71 8.93 (7.02) 2.95 (1.67)
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Chapter 4. The lysosomal aminopeptidase tripeptidyl peptidase 1 displays increased 
activity in malignant pancreatic cysts 
 
4.1 Abstract 
Incidental detection of pancreatic cysts has increased dramatically over the last decade, but risk 
stratification and clinical management remain a challenge. Mucinous cysts are precursor lesions 
to pancreatic cancer, however, the majority are indolent. Current diagnostics cannot identify 
mucinous cysts that harbor cancer or reliably differentiate these lesions from nonmucinous cysts, 
which present minimal risk of malignant progression. We previously determined that activity of 
two aspartyl proteases, gastricsin and cathepsin E, was highly increased in mucinous cysts. Using 
a global protease activity profiling technology, termed multiplex substrate profiling by mass 
spectrometry (MSP-MS), we now show that aminopeptidase activity is also elevated in mucinous 
cysts. Proteomic analysis identified the lysosomal serine protease, tripeptidyl peptidase 1 (TPP1), 
in cyst fluid and parallel reaction monitoring-based mass spectrometry demonstrated that this 
protease was significantly more abundant in mucinous cysts. In a cohort of 110 cyst fluid 
samples, TPP1 activity was increased more than 3-fold in mucinous cysts relative to 
nonmucinous cysts. Moreover, TPP1 activity is primarily associated with mucinous cysts that 
harbor high-grade dysplasia or invasive carcinoma. Measurement of TPP1 activity may improve 
early detection and treatment of these high-risk pancreatic cysts. 
 
4.2 Introduction 
Pancreatic cysts are incidentally detected in 13%-45% of patients being evaluated by abdominal 
MRI [1,2]. Clinical management is confounded by unreliable risk stratification of the malignant 
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potential of pancreatic cysts. Mucinous cysts, which include intraductal papillary mucinous 
neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), are precursor lesions to pancreatic 
cancer and should be resected if they harbor high-grade dysplasia or invasive cancer (HGD/IC). 
However, a significant portion of mucinous cysts only contain low-grade dysplasia (LGD). 
These lesions are generally considered benign and it is currently recommended that they be 
followed through surveillance. Serous cystadenomas (SCAs) and pancreatic pseudocysts, which 
are both types of nonmucinous cysts, are also common and present minimal risk to patients if 
they remain asymptomatic. Unfortunately, it remains challenging to preoperatively diagnose the 
cyst type or stage of malignant progression to determine if surgical intervention is warranted.  
  Current management guidelines for pancreatic cysts are largely based on clinical and 
radiographic features [3]. These guidelines demonstrate variable sensitivity and unsatisfactory 
specificity for diagnosing cysts with HGD/IC [4].  In an effort to improve diagnostic accuracy, 
cyst fluid is now routinely collected by endoscopic ultrasound with fine needle aspiration (EUS-
FNA) and subject to analysis. Evaluation of the tumor marker, carcinoembryonic antigen (CEA), 
is 60%-75% sensitive and 84%-93% specific for differentiating nonmucinous from mucinous 
cysts [5–7]. However, CEA levels are unable to distinguish mucinous cysts with LGD from those 
with HGD/IC. Cytological assessment of cyst fluid collected by EUS-FNA is also commonly 
performed. Although it is highly specific for identifying mucinous cysts with HGD/IC, it suffers 
from a sensitivity of only 30%-50% [8,9].  
 The limitations of clinicoradiographic and the cyst fluid diagnostics have spurred 
significant interest in identifying novel molecular biomarkers. Several cyst fluid biomarkers have 
shown promise for differentiating mucinous from nonmucinous cysts and for determining which 
mucinous cysts harbor HGD/IC.  Examples of these include microRNA [10,11], mucins [12,13], 
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glucose levels [14,15], DNA methylation [16], telomerase activity [17], and an array of DNA 
mutations [18–21]. In a recent study, we used a global protease activity profiling technology to 
identify two aspartyl proteases, gastricsin and cathepsin E, as promising biomarkers for 
differentiating mucinous from nonmucinous cysts [5]. Analysis of gastricsin activity using a 
simple, fluorescence-based assay was 95% accurate for classifying mucinous cysts. 
Immunohistochemical analysis revealed that gastricsin expression in mucinous cysts was 
primarily associated with regions of LGD; however, activity levels were unable to differentiate 
LGD from HGD/IC.  
 In the present study, we identify increased aminopeptidase activity in fluid from 
mucinous cysts and determine that the lysosomal protease TPP1 is primarily responsible for this 
activity. Using both a highly sensitive, targeted proteomics workflow and a simple, fluorescence-
based assay, we demonstrate that TPP1 levels are significantly increased in mucinous cysts 
relative to nonmucinous cysts. Interestingly, TPP1 activity is primarily associated with mucinous 
cysts with HGD/IC, which is a critical factor when determining if a cyst should be surgically 
resected.  
 
4.2 Materials and methods 
 
Sample acquisition 
The present study included 110 cyst fluid samples from patients seen at the University of 
California San Francisco (San Francisco, CA), the University of Pittsburgh Medical Center 
(Pittsburgh, PA), Indiana University School of Medicine (Indianapolis, Indiana), and Stanford 
University School of Medicine (Stanford, CA). All patients were preconsented under 
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institutional review board approved protocols. Only samples from patients that underwent 
surgical resection and pathological examination of their cystic lesion were included. Patient 
information is summarized in Table S1. Information includes the cyst type, highest degree of 
dysplasia, method of collection, and institution. All samples were stored at -80 °C prior to 
analysis and subject to a maximum of two freeze-thaw cycles.  
 
Multiplex substrate profiling by mass spectrometry assay 
The MSP-MS assay was performed as described previously [5,22]. Cyst fluid protein 
concentration was first determined through the BCA assay (Thermo Fisher, 23225). Cyst fluid 
samples were then diluted to 100 µg/mL in pH 3.5 acetate buffer or pH 7.5 phosphate buffer. The 
228 tetradecapeptide was split into two pools of 114 peptides each and diluted to 1 µmol/L in 
either acetate or phosphate buffer. Equal volumes of diluted cyst fluid and peptide pools were 
combined and incubated at room temperature. After 15 and 60 minutes, 30 µL aliquots were 
removed and protease activity was quenched with 8 mol/L guanidinium hydrochloride. Aliquots 
were then desalted using C18 tips (Rainin). The following inhibitors were included in specified 
MSP-MS assays: 1 mmol/L AEBSF (Sigma, A8456), 2 mmol/L E-64 (Sigma, E3132), 2 µmol/L 
pepstatin (Sigma, P5318), 2 mmol/L 1,10-phenanthroline (Sigma, 131337), and 10 µmol/L AAF-
CMK (Enzo, BML-PI123).  
 Mass spectrometry analysis was performed with an LTQ Orbitrap XL Mass Spectrometer 
(Thermo Fisher) coupled to an Ultra Performance Liquid Chromatography (UPLC) System 
(Waters). Peptides were separated over a C18 column (Thermo Fisher, ES800) with a 65-minute 
linear gradient from 2%-30% acetonitrile. MS spectra were acquired over an m/z range of 325-
1,500 and MS/MS spectra were obtained for the six most intense precursor ions by collision-
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induced dissociation (CID). Peak lists were generated using MSConvert and searched in Protein 
Prospector v. 5.10.0 against a database containing the sequences from the 228 tetradecapeptide 
library. Searches used a mass tolerance of 20 ppm for precursors and 0.8 Da for fragments. The 
following variable modifications were allowed: N- terminal pyroglutamate conversion from 
glutamine or glutamate and oxidation of tryptophan, proline, and tyrosine. Search outputs were 
then processed using the MSP-xtractor software (http://www.craiklab.ucsf.edu/extractor.html). 
This software extracts the P4-P4’ sequences and spectral counts for all identified cleavages. 
Spectral counts were used for relative quantification of MSP-MS results. 
 
Proteomic analysis of cyst fluid samples 
Prior to proteomic analysis, abundant serum proteins were depleted from cyst fluid samples to 
improve detection of low abundance proteases. First, 5 µL of each cyst fluid sample was added 
to columns containing resin slurry for immunodepletion of the top 12 most abundant serum 
proteins (Thermo Fisher, 85164). Samples were incubated with the resin for 1 hour at room 
temperature. Columns were then placed in collection tubes and centrifuged for two minutes at 
1000 g to collect unbound proteins. Protein concentration of the eluate was then determined by 
BCA assay (Thermo Fisher, 23225).  
 Serum depleted cyst fluid samples were then processed for proteomic analysis using a 
standard protocol. Briefly, 5 µg of cyst fluid protein was denatured in 6 mol/L urea, disulfide 
bonds were reduced with 10 mmol/L DTT, and free thiols were then alkylated with 12.5 mmol/L 
iodoacetamide. The urea concentration was diluted to 2 mol/L using 25 mmol/L ammonium 
bicarbonate and 100 ng of trypsin was added for 16 hours at 37 °C. Following trypsinization, the 
sample was desalted using a C18 tip (Rainin), dried, and resuspended in 0.1% formic acid. One 
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fifth of the cyst fluid sample was then injected onto an Orbitrap Fusion Lumos Mass 
Spectrometer (Thermo Fisher) coupled to an UPLC System (Waters). A 240 minute linear 
gradient from 2%-30% acetonitrile was used for peptide separation with a flow rate of 300 
nL/min. Survey scans were recorded over a 375-1500 m/z range and the 20 most intense 
precursor ions from each survey scan were fragmented by high-energy collision dissociation 
(HCD).  
 Peak lists were generated from MS/MS data using an in-house software called PAVA and 
searched in Protein Prospector v. 5.10.0. Peak lists were searched against all human protein 
sequences in the SwissProt database (downloaded November 1, 2017). This database was 
concatenated with a fully randomized set of entries to estimate the false discovery rate (FDR). 
For database searches, peptides sequences were matched to tryptic peptides with up to two 
missed cleavages. Carbamidomethylation of cysteine residues was used as a constant 
modification and variable modifications included oxidation of methionine, N-terminal 
pyroglutamate from glutamine, N-terminal acetylation, and loss of N-terminal methionine. The 
mass accuracy tolerance was set to 20 ppm for precursor ions and 30 ppm for fragment ions. An 
FDR of less than 1% was used for all searches. 
 
Parallel reaction monitoring of cyst fluid proteases 
To select peptides for parallel reaction monitoring (PRM) assays, we initially performed shotgun 
proteomic analysis of recombinant TPP1, gastricsin, and cathepsin E.  First, 10 ng of 
recombinant protease was denatured, reduced, alkylated, and digested. Mass spectrometry data 
was then collected using the same system, method, and search parameters as described above for 
analysis of cyst fluid proteins. From the shotgun proteomic results, we selected two of the 
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identified peptides for TPP1, gastricsin, and cathepsin E for inclusion in PRM assays (Table S4). 
Peptides were prioritized based on whether they were from the mature forms of the proteases and 
if they had been previously used in targeted proteomics assays [23]. 
 For PRM assays, 5 µL of cyst fluid protein was serum depleted as described above. The 
UPLC System was also operated using the same parameters. The MS acquisition method 
consisted of a full MS1 scan event followed by six targeted MS/MS scans for the peptides from 
TPP1, gastricsin, and cathepsin E. A 0.8 Da mass window was used for precursor ion isolation. 
The MS1 scan was performed at a resolving power of 120,000 while the MS/MS scans were 
performed at a resolving power of 30,000.  
 Relative quantitation of gastricsin and cathepsin E peptides was performed using the 
Skyline software package. Quantitation was based on the area under the curve of the eight most 
intense transitions for each peptide. To correct for potential differences in protein loading 
between runs, peak areas were normalized by the median peak area of all fragmented ions from 
shotgun proteomic analysis carried out using the same sample. The average area under the curve 
of the two peptides from each protease was then used to estimate the protein abundance in a 
given cyst fluid sample. 
 
Peptide synthesis 
Solid-phase synthesis of internally quenched fluorescent substrates was carried out using 
standard Fmoc chemistry on a Syro II automated peptide synthesizer (Biotage). The peptides 
contain a C-terminal Fmoc-Lys(dinitrophenol) (Anaspec, A23856) and a Lys-(7-
methoxcoumarin-4-acetic acid)-OH (EMD Millipore, 852095) in either the P3, P2, or P1 
position. Amino acids were coupled to Wang resin preloaded with the Fmoc-Lys(dinitrophenol). 
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The following conditions were used for coupling of Fmoc protected amino acids: 5 equivalents 
of amino acid, 4.9 equivalents of HCTU, and 20 equivalents of N-methylmorpholine. Peptides 
were cleaved from the resin by treatment with a solution of 95% trifluoroacetic acid, 2.5% 
Triisopropylsilane, and 2.5% water for 1 hour. Peptides were precipitated in cold diethyl ether 
and dried. Crude peptides were purified by HPLC and the chemical composition was confirmed 
through LC-MS analysis. 
 
TPP1 activity analysis using internally quenched fluorescent substrates 
Fluorescence-based TPP1 activity assays were performed in triplicate in black, round-bottom 
384-well plates. A final volume of 15 µL of pH 4.5 acetate buffer was used for all assays. The 
pH of 4.5 was selected on the basis of promoting TPP1 activity [24]. For analysis of TPP1 
activity in cyst fluid samples, 2 µmol/L of pepstatin was included in the acetate buffer to inhibit 
residual aspartyl protease activity. Substrate concentration was 20 µmol/L unless otherwise 
stated. Recombinant TPP1 activity was assessed at 2 nmol/L, except for when determining the 
limit of detection when concentrations down to 1.5 pmol/L were assessed. Cyst fluid assays were 
carried out using 0.75 µL of sample per well. Substrate cleavage was monitored over 1 hour with 
a Synergy HT Plate Reader (Biotek) using excitation and emission wavelengths of 328nm and 
393nm, respectively. Activity of cyst fluid samples and recombinant TPP1 is expressed as the 
initial velocity of substrate hydrolysis in relative fluorescent units per second (RFU/sec). 
 
Statistical testing and data analysis 
Two-tailed t-tests and two-way ANOVAs were used for assessing differences in protease activity 
between cysts. The specific test is indicated in text. All mass spectrometry data was log2 
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transformed prior to statistical testing. Logistic regression models were employed for cyst 
prediction and generating receiver operating characteristic (ROC) curves. Youden’s J statistic 
was used for identifying the optimal activity cutoff for assessing sensitivity and specificity of 
markers. RStudio was used to generate heatmaps, volcano plots, Venn diagrams, and ROC 
curves. GraphPad Prism was used for scatter plots, bar charts, and to fit kinetic data. Protease 
substrate specificity was visualized using iceLogo software [25]. Gene Ontology 
(http://geneontology.org/) was used for annotating proteases from proteomics data.  
 
4.4 Results 
 
Aminopeptidase activity is enhanced in mucinous cysts 
We previously used our MSP-MS assay to assess global proteolytic activity in fluid from 23 
pancreatic cysts [5]. In the present study, we analyzed an additional 12 mucinous cysts using our 
MSP-MS assay. We performed the assay under both acidic conditions and at neutral pH. In line 
with our previous results, mucinous cysts displayed increased proteolytic activity under acidic 
conditions with an increase in the average number of detected peptide cleavages relative to 
nonmucinous cysts (Fig. S1A). In contrast, both cyst types cleaved similar numbers of peptides 
at neutral pH. We then analyzed which amide bond along the 14-mers from the 228 member 
peptide library used in MSP-MS was cleaved most frequently. We did not observe any 
significant differences at neutral pH (Fig. S1B). However, under acidic conditions, a number of 
amide bonds were cleaved to a greater extent in mucinous cysts and we were particularly 
interested to observe that cleavage after the third amino acid from the N-terminus was the most 
significantly enriched (Fig. 1A). This triamino peptidase activity was not inhibited by pepstatin 
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(Fig. 1B and Fig. S1C), indicating that it was not driven by the pepstatin-sensitive aspartyl 
proteases identified previously. Pepstatin did decrease the number of detected peptide cleavages 
at the other positions that were enriched in mucinous cysts at acidic pH (B6, B8, B9, B10). 
Treatment with several other broad-spectrum protease inhibitors also failed to impact the 
observed triamino peptidase activity (Fig. S1C), however, a tripeptide chloromethylketone 
inhibitor almost completely ablated this (Fig. 1B). Halomethylketone-based inhibitors are 
generally used to target cysteine and serine proteases, providing further evidence that non-
aspartyl, protease activity is increased in mucinous cysts [26].  
 We also analyzed all 93 detected triamino peptidase cleavage events to determine if 
individual triamino peptidase cleavages were enriched in mucinous cysts (Fig. 1C). Indeed, nine 
unique events met our selectivity criteria for differentiating mucinous from nonmucinous cysts 
(+/- log2(mucinous/nonmucinous), P < 0.05). Collectively, these results suggest that non-
aspartyl, triamino peptidase activity is increased in mucinous cysts and specific peptide 
cleavages might serve as a biomarker.  
 
Proteomic analysis identifies increased levels of TPP1 in mucinous pancreatic cysts 
We next sought to identify the specific protease responsible for the increased triamino peptidase 
activity. In our previous study, we performed shotgun proteomic analysis of several cyst fluid 
samples and identified three aminopeptidases. However, all were metallopeptidases and, based 
on our inhibitor sensitivity data (Fig. S1C), are likely not driving the observed triamino peptidase 
activity. To increase the likelihood of identifying the target aminopeptidase here, we first 
performed a depletion step to remove the abundant serum proteins that are commonly detected in 
pancreatic cyst fluid. We then performed proteomic analysis and detected a total of 1,632 
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proteins between six cyst fluid samples (Table S2). Gene ontology analysis revealed that 139 of 
these proteins are proteases, including 19 aminopeptidases (Table S3). Fifty-three of the 
identified proteases were only detected in mucinous cysts, while nine were selectively present in 
nonmucinous cysts (Fig. 2A). As expected, gastricsin and cathepsin E were only identified in 
mucinous cysts. The majority of aminopeptidases were also only present in mucinous cysts and 
none were exclusively found in nonmucinous cysts (Fig. 2B and Table S3).  
 To determine which of the pepstatin-insensitive aminopeptidases was responsible for the 
increased triamino peptidase activity we considered the following features: catalytic class, pH 
optimum, and which type of cyst they were detected in (Table S3). Only seven of the identified 
aminopeptidases were serine or cysteine proteases, which could be targeted by the 
halomethylketone-based inhibitor (Fig. 1B). Of these, only TPP1 and TPP2 are reported to be 
inhibited by the specific tripeptide chloromethylketone that we used [27,28]. However, TPP2 is 
most active at neutral pH, whereas TPP1, which is normally localized to the lysosome, is known 
to be active under the acidic conditions where we observed increased triamino peptidase activity 
[24]. TPP1 was also only detected in fluid from mucinous cysts, providing further evidence that 
it is driving the enhanced activity.  
 In order to confirm TPP1’s increased abundance in mucinous cysts, we developed a PRM 
assay for relative quantitation of this protease through mass spectrometry. PRM enables the 
highly sensitive, analysis of targeted peptides for relative quantitation of proteins of interest. We 
also developed PRM assays for gastricsin and cathepsin E in order to compare the relative fold 
change in abundance for all the proteases we identified with increased activity in mucinous cysts.  
Our final PRM assay targeted two peptides per protease for a total of six peptides (Table S4).  As 
expected based on our activity and shotgun proteomics data, TPP1 displayed significantly 
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increased abundance in mucinous cysts (Fig. 2C). The log2 (fold change) in abundance for TPP1 
was 8.2, while for gastricsin and cathepsin E it was 11.6 and 9.5, respectively (Fig. S2).  
 
TPP1 activity is increased in mucinous cysts 
Due to the increased abundance of TPP1 observed through targeted proteomic analysis, we 
decided to further pursue this protease as a putative biomarker for pancreatic cysts. To this end, 
we wanted to develop a simple, fluorescent assay for activity analysis in cyst fluid. Several 
fluorescent substrates have been reported for TPP1, however, we decided to leverage our MSP-
MS assay to identify novel substrate sequences that might have improved turnover rates and 
improve the sensitivity for protease detection in clinical samples [24,29]. MSP-MS analysis of 
recombinant TPP1 confirmed that this protease readily accommodates hydrophobic amino acids 
in the P1 and P1’ positions, which flank the cleavage site (Fig. 3A). The P1 position also showed 
a slight preference for glutamine and aspartic acid. We then selected three TPP1 substrates from 
our MSP-MS library and incorporated the P3 – P4’ sequences into internally quenched 
fluorescent peptides. These substrates were selected based on several features. First, we 
identified substrates that showed time-dependent cleavage by recombinant TPP1 in our MSP-MS 
assay (Fig. S3A). Substrates also needed to generally follow the P1 and P1’ specificity of TPP1. 
We then prioritized substrates whose cleavage differentiated mucinous from nonmucinous cysts 
in our initial low pH MSP-MS analysis of cyst fluid and are likely indicative of TPP1 activity 
(Fig. 3B and Fig. S3B).  
 For synthesis of internally quenched substrates containing the selected P3 – P4’ 
sequences, we wanted to maintain the free N-terminal amine for recognition by TPP1. Therefore, 
the quencher was appended to the C-terminus while the fluorophore was conjugated to the side-
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chain amine of a lysine residue. We then tested which position on the nonprime-side of the 
scissile bond best accommodated this lysine-fluorophore (Fig. 3C and Fig. S3C). For our most 
rapidly cleaved substrate, this was the P1 position where the bulky lysine-fluorophore replaced a 
tryptophan residue. This substrate demonstrated a kcat/Km of 2.5 µmol-1s-1 and we could use this 
to quantitate as little as 95 pg/mL of TPP1 (Fig. S4).  
 We next used this substrate to directly assess the levels of TPP1 activity in 110 cyst fluid 
samples, including the 35 that were previously analyzed by MSP-MS. Cleavage of our TPP1 
substrate was increased approximately 3-fold in mucinous cysts relative to nonmucinous cysts 
(Fig. 4A). However, 27 mucinous cysts cleaved the TPP1 substrate at a lower rate than what was 
on average observed in nonmucinous cysts. Analysis of the receiver operating characteristic 
(ROC) curve for TPP1 activity revealed an area under the curve (AUC) of 0.72.  At the optimal 
cutoff of 1.1 RFU/sec, the sensitivity and specificity for TPP1 activity analysis was 62% and 
80%, respectively. This performance is comparable to what is generally reported for CEA [4], 
although within our cohort CEA at the standard cutoff of 192 ng/mL demonstrated a sensitivity 
of 65% and specificity of 94% [5]. Addition of TPP1 activity analysis to our previously 
identified aspartyl protease biomarkers did not lead to significantly improved diagnostic 
performance (Table S5).  
 We also analyzed whether TPP1 activity differentiated the different types of mucinous 
and nonmucinous cysts (Fig. S5). SCNs generally had the lowest levels of TPP1 activity, 
although this was not significant relative to pseudocysts, which where were the other type of 
nonmucinous cyst included in this study. MCNs tended to have the highest TPP1 activity, 
however, this was not significant relative to IPMNs.  
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 We next examined whether TPP1 activity levels were associated with the degree of 
dysplasia within a mucinous cyst. As mentioned previously, this is a critical distinction, as only 
cysts with HGD/IC generally need to be resected. Mucinous cysts with HGD/IC had a nearly 2-
fold increase in TPP1 activity relative to cysts with LGD (Fig. 4C). The ROC curve for TPP1 
activity displayed an AUC of 0.65 with a sensitivity of 89% and specificity of 40% (Fig. 4D). 
This performance is comparable, if not superior, to the ability of consensus guidelines to identify 
malignant mucinous cysts [30–32]. 
 
4.5 Discussion 
More than 80% of patients with newly diagnosed pancreatic cancer present with advanced 
disease, where surgical removal is no longer an option [33]. Early detection of pancreatic cysts 
presents a unique opportunity for curative resection of this highly lethal disease. Unfortunately, 
current management guidelines and diagnostic tools are unable to definitively differentiate the 
cysts that are most likely to progress to pancreatic cancer. Up to two thirds of resected pancreatic 
cysts are benign or only contain LGD with little risk of malignant progression, thus exposing 
these patients to unnecessary risk of surgical morbidity and mortality [4,31,34–36].  
 In a previous study, we identified gastricsin and cathepsin E as promising, cyst fluid-
based biomarkers for differentiating mucinous from nonmucinous pancreatic cysts [5]. Here, we 
applied MSP-MS to search for additional proteases that had both increased activity in mucinous 
cysts and could differentiate cysts based on their degree of dysplasia. We determined that 
activity of the aminopeptidase TPP1 is significantly increased in mucinous cysts, but does not 
differentiate these lesions as well as gastricsin, cathepsin E, or CEA. Within mucinous cysts, 
TPP1 activity is most highly elevated when HGD/IC is present. As a stand-alone marker, TPP1 
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activity had modest 89% sensitivity and 40% specificity for differentiating mucinous cysts with 
HGD/IC from those with LGD. However, this diagnostic performance compares favorably to the 
clinical and radiologic features, which are commonly assessed as part of current management 
guidelines [4]. TPP1 may improve the diagnostic performance of other promising cyst fluid 
biomarkers that are emerging when used in combination [16,18,21,37]. This will be a primary 
focus of future work investing TPP1 activity in pancreatic cysts.  
 TPP1 is best studied in the context of the childhood neurodegenerative disease, classic 
late-infantile form of neuronal ceroid lipofuscinoses (CLN2) and has only rarely been associated 
with tumorigenesis [38]. CLN2 is a lysosomal storage disease that is driven by mutations in 
TPP1 that lead to reduced protease activity [39]. Like many lysosomal hydrolases, TPP1 is most 
active under acidic conditions and its triamino peptidase activity has a pH optimum of 4.5 [24]. 
In line with our previous paper, our results here continue to point to increased abundance of acid-
activated, lysosomal proteases in mucinous pancreatic cysts. This observation may be related to 
the increased reliance on lysosomal function for nutrient scavenging that is observed with 
pancreatic intraepithelial neoplasia-derived pancreatic cancer [40–42]. Many acid-activated, 
lysosomal proteases exhibit increased expression in these tumors and are secreted into the 
surrounding microenvironment. The abundance of lysosomal proteases in fluid from mucinous 
cysts suggests that these enzymes are also important for maintenance and growth in cyst-derived 
pancreatic cancer. In further support of this, several other lysosomal proteases were detected 
through proteomic analysis of the cyst fluid samples included in this study. Additional studies 
will seek to determine if analysis of these acid-activated proteases improves diagnostic 
performance when combined with our current markers.  
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 In conclusion, we demonstrate here that acid-activated aminopeptidase activity is 
elevated in mucinous pancreatic cysts and this is driven by the lysosomal protease TPP1. 
Activity analysis of TPP1 is a promising biomarker for differentiating nonmucinous from 
mucinous cysts and may help address the most critical clinical challenge of identifying mucinous 
cysts with HGD/IC. Validation of these results has the potential to assist clinical decision making 
for pancreatic cysts to help ensure appropriate treatment of these challenging precursor lesions of 
pancreatic cancer. 
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4.8 Figures 
 
Figure 4.1 Identification of low pH aminopeptidase activity in mucinous cysts through 
MSP-MS. (A) The average number of detected cleavages between each amide bond (BX) within 
the 228 peptide library when the MSP-MS assay was performed at pH 3.5. A representative 14-
mer library peptide is shown below the bar chart with black circles indicating amino acids. Two-
way ANOVA was used for determining statistical significance (*P < 0.05, **P < 0.005, ***P < 
0.0005, ****P < 0.00005) (B) Heatmap displaying the number of cleavages at each amide bond 
following treatment of a mucinous cyst fluid sample with DMSO, pepstatin, Ala-Ala-Phe-
chloromethylketone (AAF-CMK), or a combination. (C) Volcano plot comparing the amount of 
cleavage at the third amide bond for individual library peptides. We detected cleavage of 93 
library peptides at this bond. Spectral counts of cleavage products were used for quantification of 
the fold change (mucinous/nonmucinous) and hypothesis testing. Dotted lines indicate P < 0.05 
and ±1 log2(fold change) and blue dots are used for triamino peptidase cleavages that met these 
criteria. 
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Figure 4.2 TPP1 abundance is increased in fluid from mucinous cysts. Venn diagrams 
showing the peptidases (A) and aminopeptidases (B) identified through shotgun proteomic 
analysis of fluid from mucinous (blue, n=3) and nonmucinous (red, n=3) cysts. (C) PRM 
analysis TPP1 peptides from nonmucinous and mucinous cyst fluid. Integrated peak areas of the 
eight most abundant transitions were used to determine the fold change 
(mucinous/nonmucinous). An unpaired, two-tailed t-test of the log2(fold change) was used for 
determining statistical significance.  
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Figure 4.3 Development of an internally quenched fluorescent substrate for TPP1 activity 
analysis in cyst fluid. (A) iceLogo depicting the substrate specificity of recombinant TPP1 
based on the 202 peptide cleavages detected through MSP-MS analysis. Amino acids that are 
significantly enriched at specific positions are shown in black (P < 0.05), while those that 
trended towards being enriched are in grey (P < 0.20).  (B) Cleavage of a peptide from the MSP-
MS library in nonmucinous and mucinous cysts. Arrow indicates that cleavage is occurring after 
the third amino acid from the N-terminus and the 7 remaining C-terminal amino acids aren’t 
shown. Spectral counts were used for relative quantification and an unpaired, two-tailed t-test 
was used for statistical testing. (C) Cleavage of internally quenched fluorescent substrates by 
recombinant TPP1. X indicates the position of the lysine-fluorophore. 
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Figure 4.4 Analysis of TPP1 activity in cyst fluid samples. (A) Comparison of TPP1 activity 
levels in nonmucinous and mucinous cysts and ROC curve (B) for differentiating these cyst 
types. (C) TPP1 activity in mucinous cysts of varying degrees of dysplasia and associated ROC 
curve (D) for distinguishing LGD from HGD/IC. For all statistical testing, an unpaired, two-
tailed t-test was used. 
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Supplementary Figure 4.1 Non-aspartyl protease activity is enriched in mucinous cysts. (A) 
Average number of detected peptide cleavages during MSP-MS analysis at pH 3.5 and 7.5. (B) 
The average number of detected cleavages between each amide bond when the MSP-MS assay 
was performed at pH 7.5. (C) Heatmap showing the number of detected cleavages at each amide 
bond following treatment of a mucinous cyst with DMSO or a panel of broad-spectrum protease 
inhibitors. For all analysis, two-way ANOVA was used for determining statistical significance 
(**P < 0.005). 
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Supplementary Figure 4.2 PRM analysis of peptides from PGC and CTSE in fluid from 
nonmucinous (NM, n=3) and mucinous (M, n=3) cysts. Peak areas of the eight most abundant 
transitions were used to determine the fold change and assess statistical significance using 
unpaired, two-tailed t-tests.  
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Supplementary Figure 4.3 TPP1 fluorescent substrate design. (A) Time dependent cleavage 
of 3 peptides in the MSP-MS library. Arrow indicates that cleavage is after the third amino acid 
and the 7 remaining C-terminal amino acids aren’t shown. (B) Triamino peptidase cleavage of 
two peptides from A by cyst fluid samples. An unpaired, two-tailed t-test was used for statistical 
testing. (C) Cleavage of internally quenched fluorescent substrates by TPP1. The position of the 
lysine-fluorophore is indicated by X. 
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Supplementary Figure 4.4 (A) Kinetic analysis of TPP1 cleavage of our most sensitive 
internally quenched fluorescent substrate. TPP1 concentration was constant at 2 nmol/L, while 
substrate concentration ranged from 0.1-50 µmol/L. (B) Determination of the limit of detection 
of TPP1 activity using internally quenched fluorescent substrate. Substrate concentration was 20 
µmol/L and TPP1 concentration ranged from 95-3000 pg/mL. 
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Supplementary Figure 4.5 TPP1 activity in different types of cysts. Statistical testing was done 
with an unpaired, two-tailed t-test. 
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Tables 
Supplementary Table 4.1 Characteristics of 110 patients analyzed in this study. 
Internal ID Diagnosis Highest grade 
of dysplasia
Cyst size 
(mm)
Collection method 
(EUS/Surgery)
Age Gender Institution
14 IPMN High 22 Surgery 60 Female UCSF
15 IPMN High 19 Surgery 69 Male UCSF
23 IPMN Low 8 Surgery 55 Female UCSF
34 IPMN High 59 Surgery 78 Male UCSF
55 IPMN High 26 Surgery 69 Female Stanford
138 IPMN Low 65 EUS 68 Male Stanford
770 IPMN High 39 Surgery 72 Female Stanford
775 IPMN High 120 Surgery 78 Male Stanford
788 IPMN High 18 Surgery 64 Male Stanford
797 IPMN High 30 Surgery 79 Female Stanford
801 IPMN High 25 Surgery 68 Male Stanford
41 IPMN Low 18 Surgery 41 Male Pittsburgh
47 IPMN Moderate 31 Surgery 47 Female Pittsburgh
51 IPMN High 20 Surgery 51 Male Pittsburgh
52 IPMN Moderate 47 Surgery 52 Female Pittsburgh
53 IPMN Low 25 Surgery 53 Female Pittsburgh
54 IPMN Moderate 38 Surgery 54 Female Pittsburgh
62 IPMN Moderate 40 Surgery 62 Female Pittsburgh
64 IPMN Moderate 47 Surgery 64 Male Pittsburgh
69 IPMN Moderate 30 Surgery 69 Female Pittsburgh
77 IPMN Moderate 65 Surgery 77 Female Pittsburgh
85 IPMN High 27 Surgery 85 Female Pittsburgh
90 IPMN High NA EUS 69 Female Indiana
169 IPMN High 35 ERCP 75 Male Indiana
1177 IPMN High 57 Surgery 67 Female Indiana
1183 IPMN High 120 Surgery 78 Male Indiana
1187 IPMN High NA Surgery 66 Female Indiana
1209 IPMN High 50 Surgery 74 Male Indiana
1217 IPMN High 23 Surgery 58 Male Indiana
1233 IPMN High NA Surgery 71 Female Indiana
1250 IPMN Low 23 Surgery 68 Female Indiana
1251 IPMN Low 25 Surgery 79 Male Indiana
1252 IPMN High 11 Surgery 72 Male Indiana
1253 IPMN High 30 Surgery 63 Female Indiana
1255 IPMN Low 37 Surgery 80 Female Indiana
1272 IPMN Low 20 Surgery 40 Female Indiana
1275 IPMN High 20 Surgery 62 Male Indiana
157 IPMN Low 35 Surgery 84 Male Stanford
685 IPMN Low 4 Surgery 71 Female Stanford
733 IPMN Low 45 EUS 78 Male Stanford
755 IPMN Moderate 60 Surgery 60 Male Stanford
760 IPMN Moderate 35 Surgery 84 Female Stanford
761 IPMN Moderate 30 Surgery 74 Female Stanford
785 IPMN Low 90 Surgery 72 Male Stanford
786 IPMN Moderate 50 Surgery 71 Female Stanford
4 MCN Moderate 23 Surgery 57 Female UCSF
6 MCN High 22 Surgery 74 Female UCSF
125 MCN High 57 Surgery 54 Female UCSF
130 MCN High 125 Surgery 47 Female UCSF
30 MCN Moderate 60 Surgery 48 Male Stanford
136 MCN Low 100 Surgery 44 Female Stanford
139 MCN Low 140 Surgery 22 Female Stanford
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Supplementary Table 4.1 (continued) 
Internal ID Diagnosis
Highest 
grade of 
dysplasia
Cyst size 
(mm)
Collection 
method 
(EUS/Surg
ery)
Age Gender Institution
686 MCN Low 125 Surgery 44 Female Stanford
716 MCN Low 30 Surgery 65 Female Stanford
720 MCN Low 45 Surgery 49 Female Stanford
752 MCN High 152 Surgery 42 Female Stanford
768 MCN Low 65 Surgery 25 Female Stanford
787 MCN Low 30 Surgery 76 Female Stanford
799 MCN Moderate 70 Surgery 31 Female Stanford
42 MCN Moderate 100 Surgery 42 Female Pittsburgh
50 MCN High 215 Surgery 50 Female Pittsburgh
59 MCN Moderate 19 Surgery 59 Female Pittsburgh
74 MCN Low 115 Surgery 74 Female Pittsburgh
75 MCN Low 30 Surgery 75 Female Pittsburgh
1152 MCN Low 18 Surgery 61 Female Indiana
1182 MCN Low 50 Surgery 25 Female Indiana
1191 MCN Low 25 Surgery 24 Female Indiana
1261 MCN Low 40 Surgery 24 Female Indiana
1263 MCN High 28 Surgery 44 Male Indiana
1265 MCN Low 30 Surgery 50 Female Indiana
1269 MCN Low 50 Surgery 57 Female Indiana
81 Pseudocyst NA 55 EUS 48 Male Stanford
98 Pseudocyst NA 219 Surgery 30 Female Stanford
101 Pseudocyst NA 40 EUS 62 Female Stanford
126 Pseudocyst NA 90 EUS 57 Male Stanford
151 Pseudocyst NA 12 Surgery 55 Female Stanford
678 Pseudocyst NA 100 Surgery 56 Female Stanford
705 Pseudocyst NA 90 Surgery 60 Male Stanford
43 Pseudocyst NA 79 EUS 43 Male Pittsburgh
49 Pseudocyst NA 98 EUS 49 Male UCSF
63 Pseudocyst NA 91 EUS 63 Male Pittsburgh
70 Pseudocyst NA 100 Surgery 70 Male Pittsburgh
78 Pseudocyst NA 31 EUS 78 Female Pittsburgh
11 Pseudocyst NA NA EUS 68 Female Indiana
50 Pseudocyst NA NA Surgery 59 Female Indiana
159 Pseudocyst NA NA EUS 67 Male Indiana
311 Pseudocyst NA NA EUS 60 Male Indiana
1142 Pseudocyst NA NA Surgery 52 Male Indiana
1178 Pseudocyst NA NA Surgery 66 Female Indiana
1180 Pseudocyst NA NA Surgery 42 Female Indiana
1191 Pseudocyst NA NA Surgery 24 Female Indiana
1230 Pseudocyst NA NA Surgery 58 Female Indiana
21 SCA NA 20 Surgery 58 Male UCSF
87 SCA NA 160 Surgery 62 Male UCSF
68 SCA NA 50 EUS 59 Male Stanford
147 SCA NA 38 EUS 45 Female Stanford
679 SCA NA 65 Surgery 70 Female Stanford
732 SCA NA 100 Surgery 43 Female Stanford
748 SCA NA 60 Surgery 66 Male Stanford
767 SCA NA 105 Surgery 47 Male Stanford
802 SCA NA 60 Surgery 75 Female Stanford
10 SCA NA 40 Surgery 55 Male Indiana
121 SCA NA 110 EUS 33 Female Indiana
128 SCA NA 25 EUS 55 Female Indiana
409 SCA NA 45 Surgery 26 Female Indiana
852 SCA NA 25 Surgery 30 Female Indiana
1053 SCA NA 12 Surgery 41 Female Indiana
1218 SCA NA 82 Surgery 76 Female Indiana
1234 SCA NA 93 Surgery 76 Male Indiana
1283 SCA NA 30 Surgery 74 Female Indiana
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Supplementary Table 4.4 Analysis of TPP1, PGC, and CTSE relative abundance by PRM. 
 
 
Protein Gene Accession	Number Peptide m/z z NM1 NM2 NM3 M1 M2 M3
Cathepsin	E CTSE P14091 QFYSVFDR 531.2562 2 2606 11146 13246 239940247 204468 1828912
Cathepsin	E CTSE P14091 SQLSEFWK 512.7585 2 4301 4068 3415 235387329 70887 4299258
Gastricsin PGC P20142 SYYSVYDLGNNR 725.8335 2 1554 3576 3630 13785954 11531615 23011535
Gastricsin PGC P20142 GLLGEFLR 452.7662 2 9996 25918 6194 28137132 24801435 64446224
Tripeptidyl-peptidase	1 TPP1 O14773 LYQQHGAGLFDVTR 535.6108 3 1391 4264 14085 12396244 817414 176277
Tripeptidyl-peptidase	1 TPP1 O14773 LFGGNFAHQASVAR 492.2565 3 1150 4447 3669 16709112 752909 288863
Peak	Area
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Supplementary Table 4.5 Diagnostic performance of TPP1 activity analysis in 110 cyst fluid 
sample. 
 
Markers AUC Sensitivity	(%) Specificity	(%)
TPP1 0.721 62 79.5
CTSE 0.828 70.4 92.3
PGC 0.979 93 100
TPP1+CTSE 0.849 74.6 87.2
TPP1+PGC 0.981 93 100
CTSE	+	PGC 0.987 94.4 100
TPP1+CTSE+PGC 0.987 94.4 100
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Chapter 5. Future directions 
5.1 Validation of a multimodal protease-based diagnostic for pancreatic cysts 
 Our work has demonstrated that protease activity is a promising new biomarker for 
differentiating pancreatic cysts based on their likelihood of malignant transformation. We have 
already shown diagnostic utility for our activity-based biomarkers in a cohort of 110 patient 
samples and our immediate next step will be validating diagnostic performance using a blinded 
patient cohort. We are currently working with a consortium of pancreatic cancer centers to 
assemble a cohort of between 200-400 patient cyst fluid samples. Prior to analysis of our 
validation cohort, we will need to establish the optimal cutoff for each activity-marker, 
determine our limit of detection, standardize sample treatment, and perform various other 
analytical validations steps.  
 In parallel, we also plan to develop a colorimetric, chemiluminescent, and enzyme-linked 
immunosorbent assay (ELISA) for each protease target. Colorimetric assays, although not as 
sensitive as fluorescence, are simple to automate and can be readily adopted into a clinical 
laboratory setting. ELISAs and chemiluminescence are both highly sensitive and might enable a 
lower limit of detection, in turn leading to improved diagnostic performance. ELISAs also have 
the potential for increased selectivity as antibodies tend to be much more specific than peptide 
substrates for assessment of a single analyte. We will assess each assay format within our 
training cohort of 110 cyst fluid samples to prioritize which to carry forward to validation. Assay 
type performance is generally dependent on the marker being targeted and it is possible that 
multiple formats will be necessary for optimal diagnostic performance. 
 Our results show that gastricsin and cathepsin E accurately differentiate mucinous from 
nonmucinous cysts, while TPP1 is better for distinguishing mucinous cysts based on their grade 
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of dysplasia. These are both critical distinctions that need to be made to ensure appropriate 
management of pancreatic cysts. Therefore, we anticipate a sequential diagnostic strategy for 
clinical use of our protease-based biomarkers. First, mucinous cysts will be identified using 
gastricsin and cathepsin E analysis. TPP1 assessment will then identify those mucinous cysts 
with HGD/IC that should be resected. As TPP1 alone is only 59% accurate for differentiating 
mucinous cysts with LGD from those with HGD/IC, we expect that the inclusion of additional 
biomarkers will significantly improve diagnostic performance. Collectively, these results suggest 
that a panel of biomarkers, including the protease-based markers identified here, will be required 
for the appropriate management of pancreatic cysts.  
 
5.2 Protease-activated chemotherapeutics for treatment of pancreatic cancer 
 Through this work we have identified several proteases whose expression is primarily 
associated with PDAC and its precursor lesions. We have primarily leveraged the activity of 
these proteases for the development of diagnostics. We are now beginning to investigate whether 
PDAC-associated proteases could be used to activate therapeutics within the tumor 
microenvironment for cancer treatment. More specifically, we plan to synthesize 
chemotherapeutics that are conjugated to a masking peptide that blocks either cellular 
permeability or target engagement. The peptide mask is stable in circulation, but can be cleaved 
by a protease within the tumor microenvironment to release the active drug. Similar strategies 
have been previously employed for both small molecules and biologics in cancer [1–3]. These 
efforts have shown promise for improving the therapeutic window of their parent agents. 
However, most efforts have been limited to targeting the mask to a single tumor-associated 
protease. Through MSP-MS, we have obtained a more global view of PDAC-associated 
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proteolysis and believe this will allow us to design masking peptides that are highly selective for 
multiple proteases within the tumor microenvironment. In combination with the diagnostic work 
proposed above, we believe these efforts may lead to highly personalized treatment regimens for 
pancreatic cancer patients.  
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